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Dementia is a main cause of dependency in stroke survivors. 
Poststroke dementia (PSD) includes any dementia after a stroke, 
irrespective of its causes, e.g. vascular dementia (VD), Alzheimer’s disease 
(AD) or mixed dementia. A huge increase in prevalence and burden of PSD 
is likely to happen because of the decline in mortality after stroke and 
ageing of populations in the coming decades worldwide. In this thesis, we 
reported the risk factors for early PSD and delayed poststroke cognitive 
decline, and the prevalence of concurrent amyloid pathology as identified 
by Pittsburgh compound B (PIB) positron emission tomography (PET) in 
PSD. Understanding the risk factors of PSD will help to devise preventive 
and treatment strategies that may reduce the burden of PSD.  
 
Objectives 
Study1: Risk factors of early PSD  
Mechanisms explaining poststroke early and delayed cognitive decline 
are complex. We set up a STroke Registry IVEstigating COGnitive decline 
(STRIVE-COG) among Chinese stroke survivors. Study 1 reported the 
findings on risk factors for early PSD.  
 
Study 2: Prevalence and predictors for delayed (15-18 months) cognitive 
decline after stroke 
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Having a stroke increases the risk of delayed dementia. However, 
mechanisms accounting for the cognitive decline are uncertain. We 
investigated the predictors for delayed poststroke cognitive decline.  
 
Subjects and Methods 
Study 1：We recruited consecutive stroke or transient ischemic attack (TIA) 
patients admitted to our acute stroke unit over 1 year. We performed 
neuropsychological assessment 3-6 months poststroke. We investigated the 
association between clinical and structural neuroimaging features with 
early PSD. We performed PIB positron PET among a subset of subjects 
with early PSD. 
 
Study 2: We performed neuropsychological assessment at baseline (i.e. 3-6 
months poststroke) and at 15-18 months poststroke. We defined cognitive 
decline as a drop of  3 points in the mini-mental state examination and/or 
increment in  1 grading of the clinical dementia rating scale. We 
investigated the association between cognitive decline with baseline 
clinical, neuropsychological, and neuroimaging features (white matter 
changes [WMC] severity, old lacunar infarct, global atrophy, frontal lobe 
atrophy [FLA], parietal lobe atrophy, medial temporal lobe atrophy). 
Among a subset of subjects (n=18) with PSD at baseline, we investigated 
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the influence of AD-like PIB retention upon the rate of cognitive decline.  
 
Results 
Study 1: Prevalence of early PSD among all recruited subjects (n=549) 
was 15.3% (n=84). Apart from age and female gender, multivariate 
regression analyses showed that risk factors for early PSD were presence of 
acute lacunar (odds ratio [OR] 2.725, 95% confidence interval [CI] 
1.364-5.434, P=0.004) or non-lacunar infarct (OR 2.809, 95%CI 
1.124-6.410,P=0.014) over no acute infarct apparent on neuroimaging, 
WMC severity (OR 1.120, 95% CI 1.037-1.210, p=0.004), FLA (OR 2.596, 
95% CI 1.080-6.241, p=0.033), and global brain atrophy (4
th
 quartile vs 1
st
 
quartile, OR 3.096, 95% CI 1.374-6.993, p=0.006). Among 19 subjects 
with early PSD who had PIB PET, 6 (31.6%) had AD-like PIB retention.  
 
Study 2: Among 452(82.3%) subjects who had completed the study, 
cognitive decline occurred in 73 (16.2%) subjects. Age, education, and 
multiple old lacunar infarcts independenty predicted cognitive decline. 
Recurrent stroke occurred only in 5.1% and was not associated with 
cognitive decline. Progressive cognitive decline occurred in 41.7% and 






Study 1: Apart from age, female gender, and presence of acute infarct 
evident in neuroimaging, chronic brain changes (WMC, global brain 
atrophy, FLA, and concurrent AD pathology) are associated with early 
PSD. 
 
Study 2: Age, education, and multiple old lacunar infarcts predicted 
cognitive decline at 15-18 months poststroke. Concurrent AD-like lesion is 




























中风存活者中建立了名为 STroke Registry IVEstigating COGnitive 
decline (STRIVE-COG) 的研究。此研究将报告早期 PSD的危险因素。 
 











早期 PSD的相关性。我们还对部分早期 PSD的病人进行了 PIB正电子
发射扫描（PIB-PET）检查。 
 
研究 2：在完成中风后 3-6 个月认知检查后的 1年，即中风后的 15-18
个月，我们完成了认知心理学的随访检查。我们将认知功能下降定义








研究 1：在所有入组的患者中（n=549），早期 PSD的发病率为 15.3%
（n=84）。多因素回归分析显示，除了年龄和性别，早期 PSD的危险
因素包括急性腔隙性梗死灶(危险比[OR] 2.725, 95% 可信区间[CI] 




度（OR 1.120, 95% CI 1.037-1.210, p=0.004），额叶萎缩（OR 2.596, 95% 
CI 1.080-6.241, p=0.033），由脑室-大脑比表示的全脑萎缩（4th 四分卫
区间 vs 1st区间, OR 3.096, 95% CI 1.374-6.993, p=0.006）。在 19个完成
了 PIB-PET 扫描的病人中，6人（31.6%）具有类似 AD的脑部淀粉样
物聚集的表现。 
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Chapter 1 Introduction  
 
1.1 An overview of stroke 
Stroke is commonly defined according to the World Health Organization 
as rapidly developing clinical signs of focal (or global) disturbance of cerebral 
function, with symptoms lasting 24 hours or longer or leading to death, with 
no apparent cause other than vascular origin. Globally, stroke is the second 
leading cause of death in those >60 years and the fifth leading cause of death 
in people aged 15 to 59 years old.
1
 In developed countries, stroke is the major 
cause of physical disability in adults, the second most common cause of 
dementia, and the third leading cause of death (after coronary-artery diseases 
and cancers).
2
 A recent systematic review and meta-analysis of 56 
population-based stroke incidence studies in the world showed that unlike 
developed countries where stroke incidence has declined by 42% over the last 
4 decades (1970–2008), stroke incidence rates in developing (low- to middle 
income) countries have increased by >100% and currently exceed the level of 
stroke incidence in the developed (high income) countries by 20%. 
3
Compared with people in developed countries, people in developing 
countries also experience a higher stroke mortality rate 
4
 and greater 
proportions of hemorrhagic strokes.
3 
In China, with 1.4 billion populations, the annual stroke mortality rate is 
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approximately 1.6 million, approximately 157 per 100 000, which has 
exceeded heart disease to become the leading cause of death and adult 
disability. Stroke causes approximately 116 deaths in population of 100 000 in 
cities and 111 deaths in rural areas. In addition, China has 2.5 million new 
stroke cases each year and 7.5 million stroke survivors.
1,5 
Poor control of vascular risk factors and limited access to acute and 
primary care are the most commonly invoked associated factors. Secondary 
prevention, an important window of opportunity for treatment, is also largely 
missed in emerging/low-middle income countries (ELMICs). Interestingly, 
limited information is available on access to care and “process measures” (a 
measure that focuses on processes that lead to desired outcomes) from these 
countries.
6 
Stroke has had a significant impact on healthcare expenditures and the 
Chinese economy. In 2004, the average fee for stroke admission was 6356 
RMB ($1000.94), which was 2 times the annual income of rural residents. The 
cost for stroke care by the government-funded hospitals was 1.17 billion RMB 
in 2003 and 8.19 billion in 2009 (117% increase annually). Now the annual 
cost of stroke care in China is approximately 40 billion RMB, 10 times higher 
than the care of cardiovascular diseases.
7, 8 
Stroke has an enormous adverse impact on patients, their families, and 
society as a whole, and is the leading cause of long-term disability.
9
 A study 
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conducted in Hong Kong showed that more than 50% of stroke patients were 
unable to live independently one year after the index stroke.
10
 Stroke often 
precludes patients from returning to work or regaining their role within the 
family. It also represents a great burden to the family, especially if the patient 
is dependent on a family member as his or her caregiver. Both the stroke 
survivor’s and the caregiver’s quality of life is adversely affected.11 
Of the stroke subtypes among the Chinese, ischemic stroke was 
predominant (66.4%), and the other subtypes were intracerebral haemorrhage 
(23.4%), subarachnoid haemorrhage (3.4%), and transient ischemic attack 
(TIA) (6.2%).
12
 The common risk factors included hypertension, diabetes 
mellitus, hyperlipidemia, smoking, and heart disease. The development of 
neuroimaging techniques, especially magnetic resonance imaging (MRI), and 
angiography techniques has greatly helped clinicians to identify the accurate 
location of infarctions and has shed light on the mechanisms of stroke. 
Measures aimed at the primary prevention of stroke, which focus on 
controlling the risk factors, have successfully reduced the incidence of stroke 
in a number of large clinical trials,
13
 and secondary prevention measures have 
successfully reduced its direct influence in acute stage 
14
 and recurrence in the 
late stage. 
15,16 
However, chronic complications following stroke, such as poststroke 
cognitive impairment and poststroke psychiatric morbidities, which are also 
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important in rehabilitation, have received less attention from clinicians. Aside 
from their strong association with stroke severity, these complications can also 
occur in independent stroke survivors. Poststroke dementia is one of those 
complications. Overall, around 25% of hospitalized stroke patients will have 
dementia when assessed within the first year after the event and rates are 
highest (>30%) in those with recurrent stroke. The presence of poststroke 





 In the past two decades, there has been increasing 
awareness among healthcare professionals in importance of cognitive 
impairment including dementia in stroke patients.
19 
 
1.2 Introduction of poststroke dementia 
Stroke increases the risk of dementia by approximate 2-9 times.
20-25
 
Poststroke dementia (PSD) is one of the main causes of dependency in 
survivors and includes any dementia after a stroke, irrespective of its 
cause—i.e. vascular, degenerative, or mixed. In pathological studies, 
cerebrovascular disease (stroke, silent infarction, microinfarction, amyloid 
angiopathy) contributes to the majority of cases of older onset dementia
26-29
 
and the attributable risk of vascular lesions for all-cause dementia is higher 
than that for cortical amyloid-beta plaques and neurofibrillary tangles 
combined.
30
 Vascular cognitive impairment is common and represents a 
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spectrum of cognitive dysfunction associated with stroke and cardiovascular 
risk factors which may be slight, moderate or severe.
31
 And more and more 
studies focused on the various domains of vascular cognitive impairments, 
including vascular risk factors, neuroimaging abnormalities as well as 
histopathologic and genetic correlates.
32-36
 Here, we only focus on the severe 
end of VCI—poststroke dementia. The cognitive consequences of stroke carry 
an associated burden of increased mortality rate, institutionalization, 
dependency and delayed discharge. 
26,37-40 
However, the determinants or predictors of early or delayed PSD were 
multifactorial, some of which were also controversial. In this section, we 
aimed to review the current understanding of PSD. Poststroke dementia will 
first be defined. Following that, foundational issues of PSD including its 
classification, pathology, prevalence, and outcome will be reviewed. 
 
Chapter 2 Poststroke Dementia 
2.1 Defining poststroke dementia 
Poststroke dementia includes all types of dementias that happen after 
stroke, irrespective of their cause. This concept is useful for patients who are 
followed up after stroke before their dementia can be diagnosed as either 
vascular dementia (VD), degenerative dementia (especially Alzheimer’s 
disease ([AD]), or mixed dementia (dementia as a result of the coexistence of 
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vascular lesions of the brain and neurodegenerative lesions). Vascular 
dementia is a direct consequence of cerebral infarcts, haemorrhages, and 
white-matter changes (WMC).
41
 But not all patients who have had a stroke, 
have VD. It might also be useful to focus on “cognitive impairment” rather 
than “dementia”, because cognitive impairment includes all cognitive 
consequences of stroke, even if they are not severe enough to meet criteria for 
dementia. Therefore, we should bear in mind that true cognitive burden of 
stroke is underestimated because cognitive impairment without dementia is 
three times more common in people who have had a stroke than in those who 
have not.
42 
In this review, PSD is defined as the presence of dementia noted after 
stroke, irrespective of presence of preexisting dementia, prior stroke history, 
mechanisms for dementia, or the latency between stroke and onset of 
dementia. Since majority of the recent studies have evaluated the presence of 
dementia at 3 – 6 months poststroke, those studies that have evaluated 
dementia longer than 6 months poststroke will be described as delayed PSD in 
this review.
21,43, 44
 Most studies on PSD have used various editions of DSM or 
ICD to define dementia poststroke.
 
2.2 Classification of poststroke dementia  
To date, a consensus on the clinical classification of PSD that is derived 
from its mechanisms and is also relevant to its management is not available 
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mainly because its exact mechanisms are yet uncertain. It is currently believed 
that PSD may involve complex interactions between vascular etiologies, brain 
lesions, brain atrophy, co-existing dementing diseases and the host factors.
45
 
The classification framework will certainly evolve as we gain better 
understanding on the mechanisms of PSD. A convenient way to classify PSD 
will be to classify according to the vascular etiology and the etiology for 
dementia.
 
2.21 Vascular etiology 
The vascular etiology of PSD includes both “stroke-related” and 
“concurrent” vascular etiology. Stroke-related vascular etiology covers present 
or previous stroke(s). Concurrent vascular etiology covers vascular etiology 
that may explain non-stroke related vascular lesion, e.g. arteriosclerosis that 
contributes to WMC or vascular etiology that explains “silent” infarct. Similar 
to stroke etiology, the vascular etiology of PSD can be classified into large 
artery disease, small vessel disease (SVD), cardioembolism, miscellaneous 
causes, hemorrhage, and PSD of undetermined vascular etiology. 
1. Large artery disease 
Large artery disease refers to atherosclerosis affecting extra or 
intracranial large artery. In Caucasians, it commonly affects extracranial 
carotid artery, while in Asians, Blacks, and Hispanics, it commonly affects 





of brain lesions associated with extracranial carotid atherosclerotic disease are 
heterogeneous, and may include cortical territorial infarct, large subcortical 
infarct, borderzone infarct (internal, anterior, posterior, superior borderzone) 
and even lacunar infarct. If the infarct hits at “strategic” areas or is of 
adequate size or frequency, it may induce PSD. Strategic area refers to 
cerebral cognitive eloquent area, which if it is affected, will cause cognitive 
impairment. Examples of “strategic” areas are thalamus, angular gyrus, genu 
of the left internal capsule, left anterior corona radiata, anterior corpus 
callosum, inferior medial temporal lobe, hippocampus, frontal lobe, and 
caudate nucleus.
47-50
 Less commonly, large artery disease may involve 
multiple arteries sequentially, inducing multiple brain lesions, and result in 
multi-infarct dementia.
 
Note that most previous studies focused only on the role of brain infarcts. 
Few studies took into account the presence of large artery itself, including 
extracranial or intracranial. A very recent pathological study showed 
intracranial atherosclerosis correlated to dementia in aging people independent 
of brain infarcts.
51
 But another hospital-based study showed the negative 
relationship between large artery disease and poststroke dementia.
52 
2. Cardioembolism 
Emboli from the heart are frequently large, causing impaction at 
intracranial large artery, resulting in extensive cortical territorial infarct. 
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Scattered emboli may occlude multiple or bilateral arteries simultaneously, 
inducing multiple large infarcts. Or that recurrent embolic stroke occurs at 
different times, causing cumulative large brain lesions. The end results of 
multiple large infarcts may again be multi-infarct dementia. Note that as in 
large artery disease, types of brain lesions associated with cardioembolism are 
also heterogeneous, including lacunar infarcts, large subcortical infarct or 
borderzone infarcts. If infarct hits at strategic areas or is extensive or multiple, 
dementia may result. And a recent study showed atrial fibrillation was 
independently associated with all forms of dementia, including VD, senile 
dementia, AD and non-specified dementia.
53
 Patients with AF are more likely 
to develop heart failure, both systolic and diastolic, which may serve as a 




3. Small Vessel Disease 
Small vessel disease is used here to include only the commonest types of 
small artery pathologies that are most prevalent among the elderly with 
vascular risk factors. Small vessel disease affects both deep and superficial 
long penetrating arteries that supply the subcortical and brainstem regions. 
The brain lesion associated with small vessel is lacunar infarct that is located 
in the subcortical or brainstem region as well as other type is WMC, which are 
located in the deep white matter or periventricular region. Due to their 





 Since present imaging modalities and techniques are not able to 
visualize small artery lesions, SVD in-vivo is diagnosed by presence of 
radiological lacunar infarcts and/or WMC in the absence of large artery 
disease, cardioembolism and other miscellaneous causes.  
The cause for the SVD-related cognitive symptoms including 
psychomotor slowing and executive deficits may lie in a disruption and 
disconnection of the frontal-subcortical pathways.
57
 Although WMC are 
distributed and diffuse in nature, they often appear more abundantly in the 
frontal lobes than in the other brain regions.
58, 59
 Moreover, WMC have been 





In this review, hemorrhagic stroke refers only to intracerebral 
hemorrhage (ICH). Although subdural, epidural and subarachnoid 
hemorrhages are all related to dementia, these non-ICH related hemorrhages 
will not be discussed in this review. The brain lesion is usually located in the 
“deep” cerebral or cerebellar region. If hemorrhage occurs at strategic area, 
such as thalamus or basal ganglia, cognitive impairment or dementia may 
result.
60-62
 Size of the hematoma or presence of ventricular extension may 
affect severity of cognitive impairment.
60
 Yet, concurrent vascular etiology 
(e.g. SVD) and brain lesions (e.g. WMC and lacunar infarcts) can also 
contribute to the dementia syndrome. Cerebral amyloid angiopathy (CAA) 
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affects small artery and has particular relevance to PSD.
63
 It is commonly 
associated with recurrent “superficial” lobar hemorrhages and dementia.64 The 
lobar hemorrhage in CAA classically occurs in the absence of hypertension 
among elderly patient. It is also found commonly in patients with AD. Rarely, 
CAA is associated with hereditary cerebral hemorrhages. However, the 
mechanism for CAA related ICH in inducing dementia is complex. Apart from 
the direct effect of recurrent cerebral hemorrhages, CAA may induce dementia 
due to concurrent AD and/or its associated concurrent brain lesions, namely 
WMC and lacunes.
65, 66
 In general, its relevance to PSD is related to the site, 
size and extent (ventricular extension) of the haematoma. 
 
5. Miscellaneous vascular etiology 
Miscellaneous subtypes of vascular etiology mainly comprise of rare 
forms of stroke disorders or CVD. Typical brain lesions may be associated 
with these diseases. Vascular etiologies of these miscellaneous subtypes of 
PSD can be further classified into hereditary, e.g. cerebral autosomal 
dominant arteriopathy with subcortical infarcts and leukoencephalopathy 
(CADASIL),
67
 non-hemorrhagic form of CAA, autoimmune vasculitis (e.g. 
systemic lupus erythematosus), hemodynamic (e.g. hypoxic-ischemic 
encephalopathy, severe heart failure, orthostatic hypotension, post-coronary 
artery bypass graft) or hypercoagulable state, e.g. antiphospholipd syndrome. 
 
6. Undetermined vascular etiology 
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Poststroke dementia of undetermined vascular etiology refers to case 
where extensive imaging and laboratory evaluations reveal no vascular 
etiology that can account for the stroke. Patients are commonly young, free of 
vascular risk factors, having stroke related cortical or large subcortical 
infarct(s). In many cases, the mechanism is presumed to be embolic in nature 
as angiography fail to reveal intra or extracranial large artery disease. Yet, 
cardiac investigation is also unrevealing. Stroke with unknown vascular 




Most studies about PSD only included ischemic stroke cases, while few 
studies include all kinds of stroke (ischemic and hemorrhagic). Also, both of 
them share the same risk factor like hypertension and the same neuroimaging 
characteristic like WMC. And the risk of PSD and its severity are not 
influenced by the type of stroke (ischaemic or haemorrhagic).
69
 It seems 
reasonable and necessary to study PSD in the cohort with ischaemic and 
hemorrhagic stroke cases.
 
2.22 Etiology of dementia 
In a patient with PSD, after determining the vascular etiology and brain 
lesion, it will be useful to determine how much does the vascular related brain 
lesion contribute to the dementia syndrome poststroke. Dementia after stroke 
may not be related to stroke or other vascular related etiology and brain lesion, 
but may be related to other dementing illnesses, e.g. AD. The most common 
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causes of PSD are VD, AD, and mixed dementia.
20, 23, 43, 52, 68, 70-73
 Alzheimer’s 
disease, mixed Alzheimer’s disease and VD account for 19-61% of patients 
with PSD. A simple way is to classify etiology of dementia into “poststroke 
VD”, “poststroke mixed dementia” and “poststroke other dementia”.  
1. Poststroke VD 
Poststroke VD refers to dementia that is predominantly attributed to the 
stroke or other concurrent vascular etiologies and related brain lesions. In 
principle, the occurrence of new onset cognitive deteriorationpoststroke
24, 52, 71
  
and/or presence of relevant radiological vascular related brain lesions suggest 
a strong vascular contribution. Relevant brain lesions include infarcts located 
at strategic sites, multiple territorial infarcts, or multiple lacunar infarcts 
associated with severe WMC.
 
2. Poststroke mixed dementia 
Poststroke mixed dementia refers to the concurrent presence of AD in a 
stroke patient with dementia. In mixed dementia, the index stroke episodes 
may or may not worsen the cognitive impairment poststroke. Information 
regarding the prestroke cognitive status is usually obtained through closed 
informants of patients. Instrument such as the Informant Questionnaire on 
Cognitive Decline (IQCODE) has been commonly used to evaluate 
objectively the presence of prestroke cognitive impairment or dementia.
43, 74, 75
 
Mixed dementia also covers case where progressive cognitive decline 
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develops poststroke in the absence of further stroke and / or new relevant 
vascular related brain lesions. In such case, concurrent AD is implicated. 
 
3. Poststroke other dementia 
This refers to the presence of other non-vascular and non-AD related 
dementing illness (e.g. dementia with Lewy bodies or chronic alcoholism) that 
either exists already prestroke or develops poststroke, and may or may not 
contribute to the dementia poststroke. In general, other dementia among 





In summary, it will be helpful from a management point of view to 
classify according to the stroke-related and/or concurrent vascular etiology, 
and then to determine how much the vascular component, or other dementing 
illnesses contribute to the dementia syndrome (i.e. etiology of dementia). To 
date, recent clinical studies have suggested that response to cognitive 
treatments vary according to vascular etiology and/or etiology for dementia. 
For example, effects of memantine or nimodipine may be better for 
subcortical VD (i.e. SVD) relative to that for large arterial related cortical 
VD,
76, 77
 while acetylcholinesterase inhibitor may be more effective in mixed 




2.23 Pathology of poststroke dementia 





and controversies regarding brain substrates that are representative of 
poststroke VD remain. Yet, pathology still plays the definitive role in 
providing information on the presence, nature and extent of vascular lesions, 
brain lesions, brain atrophy and other concurrent pathologies, e.g. AD, which 
is relevant in the overall evaluation of PSD. It has been used as the gold 
standard to evaluate the validity of various clinical diagnostic criteria for 
VD.
80, 81
 Further pathological studies will certainly contribute in unraveling 
the mechanisms of PSD. Furthermore, with the advances of imaging 
techniques, more types of pathological lesions can now be visualized by 
imaging, which are previously not detectable by standard imaging modality. 
Hence, understanding the pathological lesions for PSD provide an important 
interface for interpretation of imaging findings or development of new 
imaging techniques.
 
 In general, relevant brain lesions include cortical or large subcortical 
territorial infarct, borderzone infarct, lacunar infarct, microinfarct, 
perivascular space, hemorrhage, cortical laminar necrosis, granular atrophy, 
microbleed, WMC, hippocampal sclerosis, brain atrophy, and other 
non-vascular related pathologies, e.g. Alzheimer or cortical Lewy bodies 
pathology.
79, 82, 83
 The location, size, extent, and interaction of these lesions 
may affect its relevance to the dementia syndrome poststroke. The pathology 
related to PSD has been reviewed recently in detail.
84
 A brief overview on key 
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pathological substrates will be presented below.
 
Lacunar infarct 
Pathologically, lacunar infarct refers to small cavity of size between 
3-15mm, which is associated by either in-situ SVD (i.e. atherosclerosis or 
lipohyalinosis) or embolism from proximal sites causing occlusion of small 
vessels. Atherosclerosis affects small artery of size 200-800m and induces 
larger lacunar infarct (>5mm) due to occlusion.
85
 Lipohyalinosis affects 
arteries of size 40-200m and may cause smaller lacunar infarct (3-7mm) 
possibly by occlusion and endothelial leakage associated with breakdown of 




Perivascular space (Virchow-Robin space) 
Similar to lacunar infarct, perivascular space is also a cavity, which is 
commonly smaller than that related to lacunar infarct. It surrounds a 
penetrating artery and various hypotheses explain its occurrence, including 





White matter changes 
White matter refers to myelinated axons and glial cells that are located in 
the deep and periventricular region. White matter changes describe both 
ischemic and non-ischemic related white matter pathology. Ischemic WMC 
consist of pallor of myelin, loss of oligodendrocytes, myelins and axons, 
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cavitation with or without lipid-laden macrophages, and astrogliosis but 
without definite necrosis.
84
 Arteriosclerosis is invariably found in these areas. 
Note that the strip of white matter that is located just beneath the cortex 
(U-fiber) is usually spared due probably to adequate perfusion by unaffected 
shorter vessels located adjacent to the cortex. The cause of the ischemia can 
be multi-factorial, which may include narrowed arteries related to 
arteriosclerosis, reduced cerebral blood flow (e.g. cardiac failure, severe 
carotid artery stenosis), hyperviscosity (e.g. hyperglycemia, polycythemia, 
hyperlipidemia) and/or impaired cerebral autoregulation.
55
 The WMC may 
also be due to endothelial leakage from artery secondary to BBB dysfunction 
as a result of SVD.
86
 Furthermore, study has demonstrated that WMC may be 
indirectly due to impaired venous drainage associated with collagenous 
thickening affecting parenchymal veins or venules.
88
 In general, ischemic 





Non-ischemic WMC refers mainly to the periventricular spongioform 
zone that is associated with paucity of myelin, disrupted subependymal lining, 
and gliosis.
89
 The cause for it is probably due to altered periventricular fluid 
dynamics, which may simply be age-related with no pathological significance. 
On MRI, these pathological changes are seen as thin rim of caps or smooth 
halo.
89
 Note that small punctate deep WMC shown on MRI might not be 
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Microinfarct ranges from a few microns to 0.5mm and is characterized 
by loss of myleinated fibers in white matter or total loss of neurons in gray 
matter. Recent pathology studies have highlighted its relevance to PSD.
79, 83
 
At present, it cannot be visualized on current imaging modality.
 
Hippocampal sclerosis 
Hippocampal sclerosis in the elderly is characterized by severe neuronal 
loss and gliosis in the CA-1 and subiculum region of the hippocampus, with 
relative sparing of other hippocampal fields. It is currently believed to be due 
to ischemia secondary to systemic hypoperfusion or intrinsic CVD. 
Microbleed 
Microbleed is characterized by hemosiderin around abnormal small 
vessel, with infarction of the surrounding tissue. Although it was once thought 
to be silent, a recent study using T2*-weighted gradient-echo (GE) magnetic 
resonance imaging (MRI) demonstrated its cognitive relevance among stroke 




In principle, poststroke VD is defined by the presence of relevant 




81   
while mixed dementia is defined as concurrent presence of both vascular 
related brain lesions and significant Alzheimer’s pathology.84  
 
2.3 Frequency, incidence, and clinical determinants of poststroke 
dementia 
Hospital-based studies  
Stratification by study setting, by the inclusion or exclusion of patients 
with pre-stroke dementia, and by first ever, any (first ever or recurrent), or 
recurrent stroke results in reasonably consistent estimates of prevalence of 
early (within 1 year) post-stroke dementia across many studies. Rates of PSD 
are lowest after first ever stroke when pre-stroke dementia is excluded (12.0, 
9.6-14.4%) and highest in studies of recurrent stroke in which pre-stroke 
dementia is included (41.3, 29.6-53.1%). Rates of dementia were similar in 
those studies that looked separately at ischaemic versus haemorrhagic  
stroke
43, 44, 72, 91-93
 and the pooled analyses did not show differences between 
studies that included only ischaemic events versus those that included both 
ischaemic and haemorrhagic stroke.
 
As stated previously, there is a relative paucity of data on long-term 
cognitive outcome beyond the first year after stroke. Pooled cumulative 
incidence of PSD (excluding pre-stroke dementia) is shown in a review 
study.
69
 This study shows an initial rapid rise in dementia incidence in the 
immediate post-stroke period. Cumulative incidence of dementia increases 
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linearly at a rate of 3.0% (1.3-4.7%) per year above the initial post-stroke 
incidence of around 20% at 3-6 months. Available data suggest a rise in 
incidence after each recurrent stroke
22, 43
 in keeping with the stepwise 
progression of cognitive impairment classically associated with VD. 
Compared with the dementia incidence in controls, there is up to a nine-fold 
excess risk in stroke patients in the first year after stroke
22, 94
 and a continuing 
excess incidence thereafter, with hazard ratios of around four
22, 42




Few community-based studies have investigated the incidence of delayed 
PSD. An earlier study found that the cumulative incidence rate of new onset 
delayed PSD increased from 7% at 1 year to 48% at 25 year poststroke.
70
 The 
incidence of dementia in the first year was 9 times greater than expected and 
age, male sex, and second stroke were found to predict PSD based on 
multivariate model.
70
 In the more recent community-based studies, stroke was 
found to double the risk of dementia relative to controls who were free of 
stroke and dementia.
95, 96
 Interestingly, factors associated with lower risk of 
AD, namely young age, high education, and presence of 2 apolipoprotein E ε3 
alleles, were found to predict delayed PSD. These findings highlight the 
long-term cognitive consequence of stroke, as stroke appears to nullify the 





2.4 Imaging methods and imaging features in poststroke dementia 
The type of imaging modalities and methods that are used in PSD 
depends first, on its ability in detecting and quantifying cerebral abnormalities 
that are relevant to PSD; and second, on the availability and expertise of the 
individual center. To date, the following imaging characteristics may be found 
to be relevant to PSD: (1) type and distribution of the arterial lesions; (2) type, 
size, site, and number of vascular related brain lesions (e.g. hemorrhage, 
stroke-related infarct, silent infarct or WMC); (3) severity and distribution of 
cerebral atrophy (e.g. cortical, subcortical or regional atrophy); and (4) 
severity and pattern of cerebral blood flow, glucose metabolism. Imaging 
modalities that may be useful in the evaluation of PSD include computed 
tomography (CT), MRI (e.g. T1-, T2-, and proton density [PD] weighted, fluid 
attenuation inversion recovery [FLAIR], T2* gradient echo, arterial spin 
labeling , functional MRI), and PET (e.g. 18F-fluoro-2-deoxy-glucose [FDG], 
Pittsburgh compound B[PIB]). Structural imaging (CT and MRI) are probably 
the most commonly used. To our knowledge, relatively few studies have used 
PET imaging in the study of PSD among a large series of consecutive patients 
with stroke.  
 
Brain Infarcts 
Silent infarcts are cerebral infarcts seen on CT or MRI scans that have 
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never been associated with a corresponding neurological deficit. Most studies 
identified silent infarcts as independent predictors of PSD
43, 52, 68, 97
 except one 
study that found no relation between silent infarcts and PSD.
98
 In the Lille 
study, silent infarcts were associated with PSD in the third year but not in the 
second year,
99
 and in the Maastricht study silent infarcts were independently 
related with dementia after 1 year, but not after 1 month or 6 months.
94 
Stroke-related infarcts that were found to relate to PSD include infarct 
volume, laterality and location. The previous studies showed patients with 
large stroke infarct,
45, 100
 especially left hemisphere lesions,
45, 101, 102
 had much 
higher risk of dementia after stroke. Actually, most studies on the relation 
between stroke lesions and PSD had combined old infarcts and acute infarcts 





 or carotid vascular territory infarcts.
24, 104 
Cerebral atrophy  
Global cerebral atrophy is associated with a higher risk of         
PSD.
23, 42, 44, 52, 105, 106
 Medial temporal lobe atrophy is most common in 
patients with stroke who have preexisting dementia,
107
 but it can also be 
present in patients with stroke with no dementia. In the Lille study the 
cumulative proportion of 3-year survivors free of dementia was significantly 
lower in patients with MTLA.
108
 Medial temporal lobe atrophy clearly 
differentiates patients with dementia from those who do not have dementia 
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after a first-ever ischemic stroke, even after exclusion of patients who had 
prestroke cognitive impairment.
97, 109
 Patients with stroke with MTLA might 
have preclinical AD, which is clinically revealed by stroke.
110
 However, 
MTLA is not specific to AD, as it has also been observed in VD.
69, 111-113 
However, most studies focused mainly on the importance of global 
cortical atrophy and MTLA in PSD without taking other brain regions into 
account. But previous studies showed some other regional atrophy might also 
influence PSD, e.g. frontal lobe
114
 and parietal lobe atrophy.
115 
White matter changes 
Presence and severity of WMC are independent predictors of PSD.
92, 97
 
However, there are major potential confounding factors: cerebral atrophy, 
which is more frequent in patients with WMC; lacunar infarcts, which share a 
common pathogenesis with WMC; and stroke recurrence, which is more 






2.5 Mechanisms of stroke-associated dementia 
2.51 The role of the stroke lesion 
Stroke causes focal brain damage and yet it has global effects on cognition. 
The importance of stroke itself in the etiology of early PSD is highlighted by 
the high risk in the immediate post-stroke period, the many stroke-related 
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factors and the influence of prior stroke on rates of prestroke dementia. Global 
effects of a focal lesion may occur through strategic location (e.g. in the 
thalamus) or with large strokes. Multiple lesions in space and time are 
particularly strong associates of PSD possibly through interruption of 
intracerebral circuits.
116
 Recurrent strokes may also be associated with certain 
underlying vascular pathologies such as CAA, which is known to carry an 
increased risk of dementia.
117
 CAA may partly explain the high rate of 
dementia seen in those with recurrent events, and the fact that pre-existing 





2.52 Interactions between stroke and neurodegenerative pathology 
Neurodegenerative and vascular pathology frequently co-exist in the 
brains of elderly subjects and vascular disease in combination with 
degenerative disease lowers the threshold for dementia.
119, 120
 An interaction 
between degenerative and vascular pathology in PSD is suggested by the fact 
that several factors associated with AD (age, MTLA, female sex and family 
history of dementia) are associated with post-stroke as well as pre-stroke 
dementia and that pre-stroke cognitive decline increases the risk of PSD 
(although this may also occur because of prior cerebrovascular disease). At 
present it is unclear as to whether the interaction between stroke and 
degenerative pathology is one of simple unmasking of previous degenerative 
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change (decompensation in a brain with reduced cognitive reserve) or whether 
there is a synergistic effect of stroke, perhaps through widespread synaptic or 
perfusional changes, that accelerates existing degenerative processes. It is 
notable that PSD with more Alzheimer-type features appears more likely to 




Vascular risk factors are risk factors for AD and cerebral hypoperfusion 
and microcirculatory changes may precede the characteristic 
neuropathological and clinical changes.
121
 Some evidence for a synergistic 
interaction between vascular and degenerative pathology comes from animal 
models. Cerebral ischemia results in greater levels of inflammation, larger 
infarct size and worse cognitive performance in mice treated with 
intra-ventricular injections of amyloid.
122 
Determining the relative contributions of degenerative and vascular 
pathology in patients with PSD in-vivo is difficult. For example, degenerative 
pathology may be inferred from the presence of temporal lobe atrophy when 
in fact, there is evidence that this may also occur in association with vascular 
pathology.
123





 and those with mild cognitive impairment who 
convert to AD,
127
 may be useful in determining the presence of degenerative 
pathology in subjects with PSD. Preliminary studies suggest lower rates of 
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amyloid deposition in pure subcortical VD and PSD compared to AD.
128, 129 
 
2.53 Reduced cognitive reserve and risk of post-stroke dementia 
Non-stroke factors associated with post-stroke dementia include 
increasing age, less education, cerebral atrophy, white matter disease, 
pre-morbid disability and prestroke cognitive decline. Cerebral atrophy is 
known to occur in AD and is also seen in ageing and cerebrovascular disease 
including severe white matter disease.
130
 White matter disease predisposes to 
cognitive decline, falls and physical disability
131-133
 and mild cognitive 
impairment carries a high risk of progression to dementia.
134
 Taken together, 
these factors indicate that reduced cognitive reserve is a strong risk for PSD as 
is the case for other forms of dementia.
135, 136 
 
2.54 Mechanisms in early versus late post-stroke dementia 
As stated earlier, most data on PSD come from cross-sectional studies 
that examine patients within six months after stroke. Some late PSD cases will 
occur as a result of stroke recurrence (including silent infarction) in keeping 
with the concept of “multi-infarct dementia”. Other cases arising in the 
absence of stroke may result from progression of degenerative disease, or 
SVD/white matter disease. The factors associated with late PSD occurring in 
the absence of recurrent stroke may thus be somewhat different from those 
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associated with early PSD and may be more closely related to age, atrophy 
and vascular risk factors.  
The effect of age on late PSD is illustrated by a study on selected older 
(mean age 80 years) stroke patients who were dementia-free at 3 months, in 
whom the cumulative incidence of dementia was 24% at a mean of 3.79 years 
of follow-up.
137
 This approximates to a total cumulative incidence of around 
44% (assuming a 20% dementia rate at 3 months after stroke), which is higher 
than that seen in the pooled cumulative incidence in which the mean age of 





 and cognitive impairment without dementia
137
 after 
stroke are also associated with risk of late PSD. Multi-domain impairment 
carries greater risk than single domain impairment.
139-141
 Neuropathological 
data indicate that the majority of older subjects with late PSD have VD
137
 in 










17, 37, 38, 145
 
studies have shown that patients with PSD have higher mortality rates than 
patients without dementia, independent of age and comorbidities.
143
 The 
long-term mortality rate is two to six times higher in patients with PSD, after 
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adjustment for demographic factors, associated cardiac diseases, stroke 
severity, and stroke recurrence.
21, 37, 38, 119, 146
 In patients with pre-existing 
dementia, mortality rates are two to five times higher.
37, 146
 The increased 
mortality among patients with PSD might be the result of several factors. (1) 
Patients with dementia of any cause have high mortality.
147
 (2) Stroke 
mortality may be high in patients with dementia.
147
 (3) Dementia is associated 
with more severe vascular diseases and a higher risk of complications.
21
 (4) 
Dementia may worsen co-occurring disorders; patients with dementia may 
receive less aggressive stroke prevention,
148, 149
 and less appropriate 
treatments of associated disorders
150
 although causes of death can be similar 
in patients with and without PSD and management was similar for both 
groups in the Lille study.
 
2. Stroke Recurrence 
In the New York study,
18
 dementia diagnosed 3 months after stroke was 
associated with a three times greater increased risk of stroke recurrence 
(relative risk: 2.71; 95% CI 1.36–5.42). In another community-based study,118 
compared with cognitively normal subjects, the adjusted risk for incident 
stroke was 2.3 (95%CI, 1.7 to 3.2) in patients with dementia regardless of 
whether “questionable stroke” was included. Dementia might be a surrogate 
marker for a more severe vascular disease leading to an increased risk of 
recurrence, and less intensive stroke prevention and lack of compliance that 
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can contribute to the increased risk of recurrence.
18
 White matter changes 
could also be a confounding factor because they are associated with an 
increased risk of stroke recurrence.
146 
3. Functional outcome 
The few available data on the influence of PSD on functional outcome 
suggest that patients with PSD are more impaired and more dependent in daily 
living activities than patients with stroke who do not develop          
PSD.
20, 68, 72, 104, 151 
 
In conclusion, more than one in ten develop new dementia after first-ever 
or current stroke. The importance of the stroke itself in the causes of 
post-stroke dementia was confirmed by the strong associations between PSD 
and factors that are indicative of a greater stroke lesion burden and the 
complications of stroke. Optimum acute stroke care and secondary prevention 
of stroke are likely to be effective for reducing the burden of PSD. Further 
studies are needed to identify independent predictive factors, to develop a risk 
factor score for use in clinical practice, and to ascertain the relative 
contributions of and interactions between degenerative and vascular processes 









PART II STUDIES ON EARLY POSTSTROKE DEMENTIA AND 






















Chapter 3: Stroke Registry Investigating Cognitive decline 
(STRIVE-COG): Risk Factors for Early Poststroke Dementia (Study 1) 
3.1 Abstract 
Objective: Mechanisms explaining poststroke early and delayed cognitive 
decline are complex. We set up a STroke Registry IVEstigating COGnitive 
decline (STRIVE-COG) among Chinese stroke survivors. This study reported 
the findings on risk factors for early poststroke dementia (PSD).  
Methods: We recruited consecutive stroke or transient ischemic attack 
patients admitted to our acute stroke unit over 1 year. We performed 
neuropsychological assessment 3-6 months poststroke. We investigated the 
association between clinical and structural neuroimaging features with early 
PSD. We performed Pittsburg compound B (PIB) positron emission 
tomography (PET) among a subset of subjects with early PSD. 
Results:  Prevalence of early PSD among all recruited subjects (n=549) was 
15.3% (n=84). Apart from age and female gender, multivariate regression 
analyses showed that risk factors for early PSD were presence of acute lacunar 
(odds ratio [OR] 2.725, 95% confidence interval [CI] 1.364-5.434, P=0.004) 
or non-lacunar infarct (OR 2.809, 95%CI 1.124-6.410,P=0.014) over no acute 
infarct apparent on neuroimaging, white matter changes (WMC) severity (OR 
1.120, 95% CI 1.037-1.210, p=0.004), frontal lobe atrophy (FLA) (OR 2.596, 





 quartile vs 1
st
 quartile, OR 3.096, 95% CI 
1.374-6.993, p=0.006). Among 19 subjects with early PSD who had PIB PET, 
6 (31.6%) had Alzheimer's disease (AD)-like PIB retention.  
Conclusion: Apart from age, female gender, and presence of acute infarct 
detected in neuroimaging, chronic brain changes (WMC, global brain atrophy, 
FLA, and concurrent AD pathology) are associated with early PSD.   
 
3.2 Introduction 
Stroke has emerged to be a leading cause of morbidity and mortality in 
developing countries. The prevalence of stroke among the elderly in 
developing countries like Latin American, India, and China ranged from 6% 
to 9%.
152
 Apart from physical impairment, having a stroke is associated with 
an increased risk of both early and delayed dementia.
69
  Concurrent dementia 
in stroke is associated with increased dependence, stroke recurrence, and 
long-term mortality.
17, 18, 37, 38, 145, 152
 Worldwide, with an aging population and 
a decline in early stroke mortality because of better acute stroke care,
153
 the 
prevalence of PSD is expected to increase in the coming decade.
154
   
    
Mechanisms explaining the association between stroke and early PSD are 
probably complex.
154
 Apart from basic demographic (e.g. age, gender) clinical 
(e.g. atrial fibrillation), and stroke-related factors (e.g. size and site of stroke 
lesions), some studies suggested that chronic brain changes, such as white 
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matter changes (WMC), global brain atrophy, or regional brain atrophy (e.g. 
medial temporal lobe atrophy [MTLA]) might also contribute to the dementia 
syndrome.
69, 154
  However, most previous studies had small sample size and 
the investigation on putative variables for individual study was not 
comprehensive enough.
154
 Some studies captured only clinical and 
stroke-related factors, while ignoring measures on chronic brain changes.
72, 94, 
105
 Furthermore, although some suggested that PSD is associated with 
concurrent Alzheimer’s disease (AD),52, 108 such claims lack support from 
functional imaging (e.g. positron emission tomography [PET]) or autopsy 
findings. Moreover, only few studies had been conducted among     
Chinese.
24, 92, 155
 Currently, Chinese constitutes about one fifth of the world 
population and there are 2.5 million new stroke cases each year, with 7.5 
million stroke survivors.
156
  Relative to Caucasians, stroke burden in China is 
greater over ischemic heart disease.
5
 Since manifestation of dementia differs 
according to ethnic and cultural backgrounds,
157
 findings on PSD derived 
from other ethnicity may not be applicable to Chinese. 
 
Understanding the mechanisms of early and delayed PSD is crucial in 
devising treatment and preventive strategies for this cognitive disorder. For 
such purpose, we set up a STroke Registry IVEstigating COGnitive decline 
(STRIVE-COG) among Chinese stroke survivors. In STRIVE-COG, apart 
from collecting extensive clinical, neuropsychological, and structural 
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neuroimaging data among a large cohort of stroke survivors, we also 
performed Pittsburgh compound B (PIB) PET and 
18F-fluoro-2-deoxy-glucose (FDG) PET among a subset of subjects with PSD. 





Potential subjects of STRIVE-COG were those admitted to the acute 
stroke unit (ASU) of Prince of Wales hospital because of stroke (ischemic or 
hemorrhagic) or transient ischemic attack (TIA). Prince of Wales hospital is a 
university-affiliated hospital in Hong Kong, serving a catchment area of 0.8 
million people. Inclusion criteria for STRIVE-COG were Chinese ethnicity, 
fluent in Cantonese, ability to complete cognitive test, and provision of 
written informed consent. We excluded those with severe language, cognitive, 
motor, auditory or visual impairment that rendered patients unable to perform 
cognitive test, terminal illness with limited life expectancy, clinically 
significant depression or psychiatric co-morbidity, and refusal of participation. 
Ethics approval was obtained from the institution. The STRIVE-COG aimed 
to recruit patients who were admitted to the ASU from January 2009 through 
to December 2010 (i.e. 2 years) and to follow-up these subjects for a period of 
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5 years. This study reported the findings based on subjects recruited over the 
first year (January to December 2009).   
   
Medical history 
In this registry, we collected data on basic demography (age, gender, 
years of education, handedness), vascular risk factors, history of previous 
stroke or TIA, previous medications, and secondary prevention therapies 
during hospitalization and after discharge. The presumed causes of stroke 
were defined at discharge, including hemorrhagic stroke, ischemic stroke, and 
TIA. Ischemic stroke/TIA was classified according to the TOAST (Trial of 
Org 10172 in Acute Stroke Treatment) criterion, which categorizes ischemic 
stroke into five subtypes based on the cause: large-artery atherosclerosis 
(LAA), small-artery occlusion (SAO), cardioembolism (CE), stroke of other 
determined cause, and stroke of undetermined cause.
158
 The neurologist 
in-charge of ASU patients classified stroke subtypes based on all available 
data before the patients were discharged from the unit. We performed the 
National Institute of Health Stroke Scale (NIHSS) for all patients shortly after 
admission.
 
Patients were diagnosed as having a history of hypertension, if they had 
evidence of systolic blood pressure >140 mm Hg and/or diastolic blood 
pressure > 90 mm Hg or a history of hypertension or use of antihypertensive 
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medication. Diabetes mellitus was defined as fasting serum glucose  
7.0mmol/L, postprandial serum glucose  11.1mmol/L, or use of oral blood 
sugar-lowering drugs or insulin. Hyperlipidemia was defined as total 
cholesterol level of at least 5.2mmol/L, a low-density lipoprotein (LDL) 
cholesterol level of at least 2.6mmol/L, a triglyceride level of at least 
1.70mmol/L, and/or use of lipid lowering drugs. Ischemic heart disease was 
defined as the presence of myocardial infarction, angina pectoris, or other 
ischemic heart disease. Atrial fibrillation was diagnosed on the basis of at least 
one ECG before or during hospitalization. Smoking habit was categorized as 
ever smoking and non-smoking. Alcohol intake was recorded as ever drinking 
or non-drinking. 
We also attempted to record history of the following medical diseases: 
history of peripheral vascular disease, sleep disorders like obstructive sleep 
apnea, sickle cell anemia, hypercoagulable state (protein C deficiency, protein 
S deficiency, leukemia), pulmonary embolus, periodontal diseases including 
tooth decay or abscess, bronchitis, autoimmune disease including systemic 
lupus erthymatosus, renal disease including renal impairment or renal failure, 
epilepsy, Parkinson’s disease, Vitamin B12 deficiency, cancer, psychiatric 
disorders including depression, anxiety and other psychiatric disorders, 
surgical history including angioplasty, endarterectomy, stent, coronary artery 
bypass graft, and any other major operations. However, since prevalence of 
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the above diseases was low, ranging from 0-6%, no further analysis was 
performed on these data.  
 
Neuropsychological assessment 
All stroke/TIA patients were invited to return for a neuropsychological 
assessment at 3-6 months poststroke. We performed the clinical dementia 
rating (CDR) scale to grade the overall functional severity of cognitive 
impairment.
159
 The Chinese MMSE
160
  and the Hong Kong Montreal 
Cognitive Assessment (HK-MoCA)
161
  were used to index general cognition. 
We administered the Chinese version of the informant questionnaire on 
cognitive decline in the elderly (IQCODE) upon the subject’s reliable 
informant or caregiver to assess prestroke cognitive condition.
162
 The final 
score is the average of all scored items. We defined prestroke dementia when 
the average score was ≥ 4 or the subjects had known history of dementia. We 
used Chinese geriatric depression scale (GDS) to assess severity of depressive 
mood.
163
 Trained psychologists performed all the above tests. Subjects with 
CDR ≥1 were further invited for another assessment by neurologists 
specialized in dementia (Vincent Mok, Lisa Au) to confirm a diagnosis of 










Structural and vascular imaging  
A non-contrast brain computed tomography (CT) was performed with a 
multidetector row clinical CT scanner (10-mm slice thickness at 10-mm 
intervals supratentorially and 5-mm slice thickness and 5-mm intervals 
through the posterior fossa) for all subjects upon arrival to accident and 
emergency department before admission to ASU. The CT imaging would be 
reconstructed into axial and coronal imaging for subsequent visual ratings. We 
performed brain magnetic resonance imaging (MRI) upon selected patients 
within 1 week of hospital admission, e.g. those with non-hemorrhagic and 
non-cardioembolic ischemic stroke, unclassified stroke etiology, without 
contraindication for MRI (e.g. unstable medical condition, metallic implants, 
claustrophobia). All MRI examinations were performed either on a 1.5 T 
scanner (Sonata, Siemens Medical, Erlangen, Germany) or a 3.0 T sacnner 
(Achieva 3.0 T TX Series, Philips Medical System, Best, the Netherlands) 
using standard protocols. The sequences include the following: diffusion 
weighted imaging (DWI), axial gradient echo (GE), axial spin echo (SE) 
T1-weighted fast field echo (FFE), turbo spin echo (TSE) proton density (PD) 
and T2 –weighted, axial FLAIR (Fluid attenuated inversion recovery), and 
time-of-flight (TOF) MR angiography (MRA) for 1.5-T MRI; and DWI, blood 
sensitive venous bold sequence, axial SE T1-weighted FFE, TSE 
T2 –weighted, axial FLAIR, TOF MRA for 3-T MRI.  
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Trained technicians also performed transcranial Doppler (TCD) and 
carotid duplex ultrasound according to standard protocol
165
for evaluation of 
intracranial and extracranial arteries, respectively, for patients with 
non-hemorrhagic and non-cardioembolic ischemic stroke / TIA. For TCD, the 
criteria for stenotic arteries were defined by the peak systolic flow velocity as 
follows: ≥140 cm/s for the middle cerebral artery, ≥ 120 cm/s for the anterior 
cerebral artery, ≥ 100 cm/s for the posterior cerebral artery and vertebrobasilar 
artery, and ≥ 120 cm/s for the siphon internal carotid artery.165 Presence of 
any intracranial large artery stenosis on MRA and extracranial artery stenosis 
on carotid duplex was defined by a stenosis of ≥ 50%. In cases with 
conflicting TCD and MRA results, presence of intracranial artery stenosis was 




A trained neurologist (Yang Jie) who was blinded to the clinical and 
cognitive data recorded the following measures on stroke-related lesions: 
presence of hemorrhage, acute infarct measures (size and location), and 
laterality of ischemic or hemorrhagic lesions. The infarct size was categorized 
as lacunar if the infarction was between 3 and 20 mm in diameter; or 
non-lacunar if the infarct size was > 20mm. Location of acute infarct was 
classified as cortical, subcortical white matter, deep (basal ganglia, internal 
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capsule, or thalamus), or infratentorial (cerebellum, brainstem). Acute infarct 
was defined by the presence of hyperintense MRI DWI lesions with 
corresponding hypointensity in the apparent diffusion coefficient map or 
hypodense lesions on CT that were relevant to the acute neurological signs 
and symptoms.
166
 With reference to subject’s handedness, laterality of lesion 
was labeled as dominant or non-dominant. 
 
 
Chronic brain changes (white matter changes [WMC], old infarct, global and 
regional brain atrophy)  
The same neurologist (JY) who recorded stroke-related lesions also recorded 
following measures on chronic brain changes:  
1. WMC - Severity of WMC was rated on images obtained with FLAIR 
or CT scan using the Age-Related White Matter Changes Scale (ARWMC).
167
 
We recorded the total and global ARWMC scores. The global score (range 
0-3) is the score of the most severe region, with score 0, 1, 2, and 3 




2. Old infarct - We recorded the presence of old lacunar and old 
non-lacunar infarcts, which were not clinically relevant to the index stroke. 
Old lacunar infarct was defined as hypodense foci 3 mm to 20mm larger on 
CT scan or as hypointense lesion on FLAIR (with or without a hyerintense 
rim) and on T1-weighted images. We recorded the total number and the 
 42 
 
location of old lacunar infarct. Location of old lacunar infarct was classified 
as frontal lobe, parieto-occipital lobe, basal ganglia, thalamus and 
infratentorial region.
169
 We recorded only the number of old non-lacunar 
infarct. 
 
3. Brain atrophy - We used the ventricle-to-brain ratio (VBR) to index 
global or subcortical atrophy. The VBR was calculated as the mean of the 
biventricular width at the level of the frontal and occipital horns and at the 
level of the body of the caudate nuclei divided by the corresponding brain 
width at those levels on either MRI or CT.
170
 We graded frontal lobe atrophy 
(FLA)（Figure 3-1）and parietal lobe atrophy (PLA) using a 3-point (0-2) 
scale.
171
 Rating of FLA was carried out on axial T1-weighted MRI or CT 
images. Rating of PLA was carried out on coronal T1-weighted MRI or CT 
oblique coronal reconstructed images. Subject with a rating of  1was 
classified as having FLA or PLA. Medial temporal lobe atrophy (MTLA) was 
rated on coronal images on T1-weighted MRI or CT oblique coronal 
reconstructed images using the Scheltens’ scale.172 Subject with a rating of  2 
was classified as having MTLA. For subjects who had both CT and MRI, 
above ratings were performed only upon MRI. 
 
To investigate whether the visual rating methods for WMC, VBR, FLA, 
PLA, and MTLA are applicable to both CT and MRI, we performed 
intermodality agreement between CT and MRI based on random selection of 
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30 subjects’ scans. The agreement for WMC (intraclass correlation coefficient 
ICC 0.82), VBR (ICC 0.85), FLA (percentage of agreement 0.94), left 
MTLA (ICC 0.86), was excellent. There was also good agreement for PLA 
(percentage of agreement, 0.78) and right MTLA (ICC 0.58). The intrarater 
agreement between two measurements within 6 months for a single rater (JY) 
among random selection of 30 scans was also excellent for CT (WMC ICC, 
0.93, VBR ICC 0.92, FLA percentage of agreement 0.99, PLA 
percentage of agreement 0.99, left MTLA ICC 0.99, right MTLA ICC 
0.98 ); and MRI (WMC ICC 0.96, VBR ICC, 0.95, FLA percentage of 
agreement 0.99, PLA percentage of agreement 0.99, left MTLA ICC, 0.92, 
right MTAICC, 0.94 ).  
 
FDG and PIB-PET scan 
Patients with early PSD were potentially eligible for FDG and PIB PET. 
Exclusion criteria for PET imaging were as follow: 1. patients with known AD 
or other degenerative dementing disorders (e.g. frontotemporal dementia) 
before stroke; 2. patients without reliable informants; 3. patients who suffered 
from severe stroke with significant cognitive and motor disability; and 4. those 
who refused to participate in this PET study. We obtained a separate ethics 
approval from the institution for this PET study and all subjects and their 
caregivers provided written informed consent. Brain CT transmission and PET 
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imaging began after PIB injection for 5, 35 and 60 minutes and then static 
imaging began at 30 minutes after FDG administration. All images were 
reviewed by a specialist in nuclear medicine (Eric Leung). Subjects with 
predominant increase in PIB binding observed visually at the frontal cortex, 
posterior cingulate, precuneus, caudate, parietal cortex, and/or lateral temporal 
cortex were considered as having AD-like PIB binding.
128
 On FDG PET, 
presence of bilateral temporoparietal and posterior cingulate hypometabolism 




We compared data between the recruited and excluded subjects and 
between those with and without early PSD using χ2, unpaired 2-taied t test, or 
Mann-Whitney U test. Difference with a p value <0.05 was considered 
significant. Regression modeling was used to identify factors that 
independently associated with early PSD with variables showing P <0.05 in 
the univariate tests. For the investigation on the risk factors for early PSD, we 
analyzed the following variables: basic demographics, stroke subtypes, 
vascular risk factors (smoking, alcohol consumption, hypertension, 
hyperliperdemia, diabetes mellitus, previous TIA, previous ischemic stroke, 
previous hemorrhagic stroke, atrial fibrillation, ischemic heart disease, 
congestive heart failure), GDS, measures of stroke-related lesions (acute 
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infarcts, hemorrhage), presence of intracranial and extracranial large artery 
stenosis, and chronic brain changes (WMC, old infarcts, VBR, FLA, PLA, 
MTLA). Because the prevalence of “stroke of other determined cause” (n=17, 
3.1%) and “stroke of undetermined cause” (n=24, 4.4%) was low, we 
combined subjects of these 2 groups under one category (other ischemic 
stroke subtypes) for statistical analysis. For atrophy measures, we used the 
presence or absence of FLA, PLA, and MTLA. For global brain atrophy, we 
compared the percentage between the 4 quartiles. For ARWMC, we used the 
total score as continuous variable. Statistical tests were performed by SPSS 
for Windows (release 16.0, SPSS Inc). 
 
3.4 Results 
Between January and December 2009, 1006 stroke cases were admitted into 
the ASU. Among them, 549(54.5%) subjects were finally recruited for 
analysis. We excluded 457(45.5%) patients because of following reasons: 1. 
died before assessments (n=114, 11.3%); 2. patients had another stroke before 
assessment (n=47, 4.6%); 3. unable to communicate (n=70, 7.0%) because of 
severe aphasia(n=10, 0.9%), non-Cantonese speakers (n=4, 0.3%), severe 
visual impairment(n=5, 0.4%), severe hearing impairment(n=6, 0.5%), and 
severe dementia (n=45, 4.4%); 4. severe physical disability rendering 
participation in cognitive assessment impossible (n=26, 2.5%); 5. hospitalized 
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at time of assessment because of non-stroke related illnesses (n=15, 1.5%); 6. 
refusal to participate (n=84, 8.3%); 7. could not be contacted (n=53, 5.2%) 
because of wrong identification number or wrong phone contact number 
(n=47, 4.7%) or not residing in Hong Kong(n=6, 0.5%); 8. non-Chinese(n=10, 
10%); 9. active psychiatric diseases (n=3, 0.3%); and 10. incomplete data on 
important information (n=35, 3.5%). 
The median age (interquartile-range, IQR) of the subjects was 71(61-79) 
years, with 55.4% male. The median (IQR) NIHSS was 4 (2-7). Excluded 
patients were older (P<0.001), had higher NIHSS (P<0.001), and had higher 
proportion having CE, intracerebral hemorrhage (ICH), and other stroke types 
(table 3-1). Table 3-2 presents the characteristics of the included subjects.  
Among patients with ischemic stroke / TIA (n=511), 241 subjects (47.1%) 
had no acute infarct evident on neuroimaging. Majority of these subjects had 
only CT scan without MRI (n=161, 66.8%). Among TIA subjects (n=62), 
acute infarct was not evident on neuroimaging for most cases (n=57, 91.9%). 
Among subjects without apparent acute infarct, proportion of subjects who 
had LAD, SAO, CE, and other stroke subtypes was 19.4%, 53.7%, 19.8%, and 
7%, respectively.   
Prevalence of early PSD among all recruited subjects (n=549), among 
new-onset dementia (n=501), and among first-ever stroke (n=444) was 15.3% 
(n=84), 10.2% (n=51), and 13.9% (n=62) respectively. Table 3-3 compares the 
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characteristics between those with and without early PSD. Multivariate 
regression analyses found that independent risk factors for PSD among all 
subjects were age (odds ratio [OR] 1.124, 95% confidence interval [CI] 
1.007-1.172, p<0.001), female gender (OR 1.957, 95% CI 1.039-3.676, 
p=0.038), acute lacunar (OR 2.725, 95%CI 1.364-5.434, p=0.004) or 
non-lacunar (OR 2.809, 95%CI 1.124-6.410, p=0.014) infarct versus no acute 
infarct detected on neuroimaging, total WMC score (OR 1.120, 95%CI 
1.037-1.210, p=0.004); FLA (OR 2.596, 95%CI 1.080-6.241, p=0.033), VBR 
at second quartile (OR 5.464, 95% CI 1.698-17.543, p=0.004), third quartile 
(OR 2.493, 95% CI 1.112-5.586, p=0.027), and fourth quartile (OR 3.096, 
95% CI 1.374-6.993, p=0.006) over first quartile of VBR.(Table 3-4) Age (OR 
1.087, 95%CI 1.018-1.160, p=0.012) and MTLA (OR 3.367, 95%CI 
1.101-10.417, p=0.035) were the only risk factors for new-onset dementia, 
while risk factors for first-ever stroke were age (OR 1.128， 95%CI 
1.070-1.188, p<0.001), female gender (OR 2.809, 95%CI 1.267-6.211, 
p=0.011), and VBR at second quartile (OR 4.975, 95% CI 1.208-20.408, 
p=0.026), third quartile (OR 2.739, 95% CI 1.042-7.246, p=0.041), and fourth 
quartile (OR 3.318, 95% CI 1.187-8.246, p=0.021) over first quartile of VBR.  
Among the 19 EPSD patients stroke with PIB PET imaging, six (31.6%) 
had AD-like PIB binding (Figure 3-2). The FDG-PET of these 6 subjects also 
showed temporoparietal and posterior cingulate hypometablism, suggestive of 
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AD The basic demographic features, cognitive performance, and 
neuroimaging features were similar between PSD patients with and without 
AD-like PIB binding (Table 3-5). 
 
3.5 Discussion 
In this study, we found that apart from age, female gender, and presence of 
acute infarct evident on neuroimaging, chronic brain changes including WMC 
severity and various measures of brain atrophy were associated with early 
PSD. Furthermore, we found that among a subset of subjects with early PSD 
who had PET, AD-like PIB retention typical of AD was detected in about 30%. 
To date, this is one of the largest prospective hospital-based studies in early 
PSD that analyzed extensive clinical and neuroimaging data.  
In this study, prevalence of early PSD among all subjects was 15.3%. 
This is slightly lower than that reported in our earlier study of a smaller scale 
(20%). Note however that we had excluded 4.4% of patients with significant 
dementia in this study; hence the prevalence of early PSD of this study is 
probably identical to that of the earlier study. We excluded those with 
significant dementia who were unable to communicate because 
STRIVE-COG aimed to study patients with early and delayed cognitive 
decline who may still benefit from symptomatic or preventive treatment. 
Using this conservative prevalence rate of 15% and assuming there are about 
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7 million stroke survivors in China, we estimate that there may be 1 million 
Chinese suffering from PSD.  
Concur with previous studies, we found that increasing age and female 
gender were basic demographic features correlated with early PSD.
52, 173
  
None of the examined clinical diseases were found to correlate with PSD. As 
to the stroke-related lesion, we found that the mere presence of acute lacunar 
or non-lacunar infarct evident on neuroimaging was already sufficient to 
increase the odds of having early PSD. Some prior studies found that laterality 
(e.g. left sided), site (e.g. anterior corona radiata), or size (e.g. larger infarct) 
of infarct was associated with PSD.
45, 97, 100
  In our study, note that majority 
of subjects without apparent acute infarct had only CT scans (66.8%) and a 
quarter of them had only TIA (23.7%) or were classified as having SAO 
stroke subtype (53.7%). These subjects probably suffered from less severe 
ischemic damage (e.g. a shorter period of cerebral ischemia or a smaller 
infarct) relative to those with acute infarct evident on neuroimaging and were 
thus less likely to have dementia. Whether treatment that can reduce the 
cerebral damage of the ischemic insult during the hyperacute stage (e.g. 
thrombolysis) can reduce risk of PSD requires further investigation to 
determine. Of further note is that although severe ischemic infarct associated 
with significant neurological disability might not be apparent in the initial CT 
during the hyperacute stage, such cases were unlikely to be common because 
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as a standard practice in our ASU, a repeated CT or MRI would be arranged 
later to confirm the nature or extent of the lesion. In this study, later scans 
were used for data analysis. 
 
    We found that chronic brain changes, including WMC and various 
measures of brain atrophy, were risk factors for early PSD. The findings that 
WMC,
45, 92




 were associated with PSD 
were consistent with previous studies. Age-related WMC were considered 
manifesta tion of small vessel disease (SVD). Cognitive impairment in WMC 
is believed to be mediated by disruption of frontal-subcortical circuits and/or 
by its association with brain atrophy.
174, 175
 However, a very recent study 
showed brain atrophy and WML are independently related to cognitive 
impairment in small vessel disease. MTA, subcortical, and cortical atrophy 
seem to potentiate the effect of WML and lacunes on cognitive decline.
176
 
Hence, the relationship between brain atrophy and WMC still need to be 
investigated. Very few studies had evaluated the cognitive relevance of FLA in 
stroke patients. In our earlier studies, we found that FLA was associated with 
cognitive impairment among patients with SVD.
155, 169
 The present study 
further showed that FLA was associated with dementia among stroke patients 
in general.   
To date, this is the first study using PIB PET to evaluate the etiology of 
early PSD. Our prevalence of concurrent PIB retention in early PSD (31.6%) 
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is identical to that found in a recent study (31.1%) among patients with 
subcortical VD.
177
 However, different to this recent study is that we were 
unable to detect any apparent difference in terms of age, severity levels of 
cognitive impairment, number of lacunar infarct, and severity of brain atrophy 
between PIB positive and PIB negative patients.
177
 Noteworthy is that 
AD-like PIB retention might also be found in about 30% of cognitively 
normal elderly subjects.
178
 In this study, we were unable to determine whether 
the PIB retention was contributory to or coincidental with the dementia 
syndrome. A longitudinal study comparing the rate of cognitive decline 
between PIB positive and negative patients may help to understand the impact 
of PIB retention in PSD. 
 
The strengths of our study are its large sample size, its prospective design, 
and the evaluation of a large number of clinical, neuropsychological, and 
neuroimaging data. Certain limitations should however be addressed. First, 
only half of the cases had MRI. Smaller acute or old lacunar infarcts and mild 
severity of WMC could not be visualized well by CT. We might thus have 
underestimated the cognitive impact of these lesions. Yet, this registry 
probably reflects the reality of many stroke units where MRI is not easily 
accessible, especially those in developing countries like China, where the 
burden of PSD is the greatest. Second, we used visual, rather than volumetric 
methods for assessment of chronic brain changes. Hence, despite we obtained 
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good to excellent intermodality and intrarater agreement for our visual 
methods, the influence of smaller volumetric changes of these chronic brain 
changes might not be detected. Last, despite this is the first prospective study 
utilizing PIB PET in the evaluation of PSD, the proportion of early PSD 
patients who eventually had PIB-PET was small (22.6%) and PIB retention 
was found only in 6 subjects.  Furthermore, PET imaging was not performed 
among stroke subjects without dementia. Larger studies are thus needed to 
confirm the prevalence of PIB retention in PSD and to compare the difference 
in prevalence between those with and without PSD, and between PIB positive 
and negative PSD patients.  
In conclusion, findings of STRIVE-COG highlight that apart from age, 
female gender, and acute lacunar or larger infarct apparent on neuroimaging, 
chronic brain changes including WMC, global atrophy, FLA, and MTLA are 
important risk factors for early PSD. Concurrent AD pathology may also be 
found in about 30% in these patients. Apart from preventing first and recurrent 
stroke, strategies targeting chronic brain changes
69
 may probably also help to 
reduce the risk of PSD if stroke event does occur. In fact, recent studies 
showed that these chronic brain changes are also associated with reduced 
survival in the elderly.
179, 180
 Since these chronic brain changes evolve long 
before the stroke or dementia occurs, intervention may still be possible at the 
preclinical stage. Further studies on understanding predictors for progression 
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of these chronic brain changes and on evaluating potential treatments targeting 








































Table 3- 1.  
Comparison between excluded and included patients 
 






























Age, year, median (IQR) 75(54-82) 71(61-79) <0.001 
Admitted NIHSS, median(IQR) 7(3-20) 4(2-7) <0.001 
Male 233(51.0) 304(51.4） 0.165 
Stroke subtypes   0.001 
Large-artery atherosclerosis 104(22.8) 142(25.9)  
Small-artery occlusion  102(22.3) 159(29.0)  
Cardioembolism  121(26.5) 107(19.5)  
  ntracranial hemorrhage 58(12.7) 38(6.9)  
  Transient Ischemic Attack 37(8.1) 62(11.3)  




Table 3- 2.  
Basic demographic, clinical, neuropsychological data, and neuroimaging 
features of all included subjects 
  n=549 
Basic demographic features  
Age, year, median (IQR) 71(61-79) 
Female 244(44.4) 
Education, year, median (IQR) 5(1-9) 
Clinical features or vascular risk factors  
Smoking 154(28.1) 
Alcohol consumption 54(9.8) 
Hypertension 387(70.5) 
Hyperliperdemia 313(57.0) 
Diabetes mellitus 212(38.6) 
Previous transient ischemic attack 21(3.8) 
Previous ischemic stroke 70(12.8) 
Previous hemorrhagic stroke 18(3.3) 
Atrial fibrillation 95(17.3) 
Ischemic heart disease 54(9.8) 
Congestive heart failure 20(3.6) 
Intracranial large artery stenosis 186(51.8) 
Extracranial large artery stenosis 56(17.1) 
Intra and extracranial large artery stenosis 213(65.9) 
Neuropsychological features  
Prestroke IQCODE mean score (SD) 3.11(3.00-3.39) 
Prestroke dementia 48(10.4) 
Mini-mental state examination, median (IQR) 26(20-28) 
Montreal Cognitive Assessment, median (IQR)  21(15-25) 




Geriatric depression scale  5(3-8) 
Stroke-related lesions  
Size of acute infarction  
No infarction evident on neuroimaging 241(47.2) 
Non-lacunar    134(26.2) 
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Values are number (%) unless otherwise stated; SD = standard deviation; 
IQR=interquartile range; ARWMC= age-related white matter changes; 
IQCODE=Informant Questionnaire on Cognitive Decline in the Elderly; * 246 
(45.2%) subjects had MRI  
 
Lacunar 136(26.6) 
Location of acute infarction  
Cortical 62(23.0) 




Dominant hemisphere 122(45.2) 
Non-dominant hemisphere 148(54.9) 
Neuroimaging features on chronic brain changes*  
ARWMC scale total score, median (IQR) 2(0-6) 





Presence of old lacunar infarcts 257(47.1) 
Number of old lacunar infarcts, median (IQR) 0(0-2) 
Presence of old total infarcts 285(52.4) 
Number of old total infarcts, median (IQR) 1(0-2) 






 quartile 0.31(0.01) 
3
rd
 quartile 0.34(0.01) 
4
th
 quartile 0.39(0.04) 
Presence of frontal lobe atrophy    64(11.7) 
Presence of parietal lobe atrophy 54(10.0) 
Medial temporal lobe atrophy grading  








Table 3- 3. 
Comparison between subjects with and without early poststroke 
dementia 





Basic demographic features    
Age, year, median (IQR) 69(60-77) 80.5(74-86) <0.001 
Female 189(41.9) 49(58.3) 0.005 
Education, year, median (IQR) 6(2-9) 2(0-6) <0.001 
Clinical disease or vascular risk factors 
Smoking 136(30.2) 15(17.9) 0.021 
Alcohol consumption 45(10.0) 5(6.0) 0.245 
Hypertension 311(69.0) 67(79.8) 0.046 
Hyperliperdemia 268(59.4) 40(47.6) 0.044 
Diabetes mellitus 173(38.4) 34(40.5) 0.715 
Previous transient ischemic attack 19(4.2) 2(2.4) 0.399 
Previous ischemic stroke 51(11.3) 16(19.0) 0.049 
Previous hemorrhagic stroke 14(3.1) 4(4.8) 0.460 
Atrial fibrillation 72(16.0) 20(23.8) 0.080 
Ischemic heart disease 40(8.9) 12(4.3) 0.124 
Congestive heart failure 15(3.3) 5(6.0) 0.274 
Intracranial large artery stenosis 165(51.1) 17(58.6) 0.437 
Extracranial large artery stenosis 45(15.6) 89(25.8） 0.148 
Intra and extracranial large artery stenosis 186(64.6) 22(78.6) 0.136 
Neuropsychological features    
Prestroke IQCODE score, median(IQR) 3.07(3.00-3.27) 3.70(3.08-4.46) <0.001 
Prestroke dementia 15(3.9) 33(41.8) <0.001 
Mini-mental state examination, 
median(IQR) 
27(23-29) 12(8-16) <0.001 
Montreal Cognitive Assessment, 
median(IQR) 
21(16-25) 9(6-12) <0.001 
Geriatric depression scale, median(IQR) 5(2-8) 9(6-12) <0.001 
Stroke-related lesions    
Size of acute infarction   0.002 
No infarction evident on 
neuroimaging 
202(47.6) 33(44.0)  
Non-lacunar 100(23.6) 31(41.3)  
Lacunar 122(28.8) 11(14.7)  
Location of acute infarction   0.252 
 Cortical 48(21.6) 14(33.7)  
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 Subcortical white matter  91(41.0) 18(42.9)  
Deep 31(14.0) 3(7.1)  
Infratentorial 52(23.4) 7(16.7)  
Lateralization   0.182 
Dominant hemisphere 79(35.6) 17(40.5)  
Non-dominant hemisphere 143(64.4) 25(59.5)  
Neuroimaging features on chronic brain changes 
ARWMC scale total score, median (IQR) 1(0-5) 6(2-8) <0.001 
Number of old lacunar infarcts, median 
(IQR) 
0(0-2) 1(0-3) <0.001 
Number of old total infarcts, median 
(IQR) 
0(0-2) 2(0-3) <0.001 
Ventricular-brain ratio, n (%) for each 
quartile 
  <0.001 
1
st 
quartile 129(30.0) 6(7.1)  
2
nd
 quartile 133(31.1) 19(22.6)  
3
rd
 quartile 93(21.7) 14(16.7)  
4
th
 quartile 73(17.1) 45(53.6)  
Frontal lobe atrophy  48(10.7) 16(19.0) 0.032 
Parietal lobe atrophy 36(8.1) 16(19.0) 0.002 
Medial temporal lobe atrophy grading   <0.001 
0-1 321(72.5) 32(38.1)  




Table 3- 4. 
Multiple regression analysis for early poststroke dementia  
 





























Age 0.117 1.124 <0.001 1.077 -1.172 
Female 0.671 1.957 0.038 1.039 -3.676 
Frontal lobe atrophy 0.954 2.596 0.033 1.080 -6.241 















  1.130 3.096 0.006 1.374 -6.993 
ARWMC scale total score  0.114 1.120 0.004 1.037 -1.210 
Acute infarct size      
Lacunar vs no acute infarct 1.002 2.725 0.004 1.364 -5.434 
Non-lacunar vs no acute infarct 1.034 2.809 0.014 1.124 -6.410 
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Table 3- 5. 
Comparison between poststroke dementia patients with and without PIB 
retention 
 
Values are number (%) unless otherwise stated; * = median (IQR);  
























Age* 80(67-85.5) 78(73.3-80.7) 0.579 
Male 4(30.8%) 3(50.5%) 0.423 
Education, years* 3(0-9) 3(1-10) 0.743 
Mini-mental state examination * 13(9-17.5) 13.5(9.7-21.2) 0.701 
Montreal Cognitive Assessment * 9(6.5-16.5) 10(8-18.5) 0.518 
Prestroke IQCODE* 3.91(3.33-4.50) 3.80(3.10-4.28) 0.443 
ARWMC scale total score* 8(1.5-12) 6(1.5-9) 0.701 
Old lacunar infarct number* 1(0-5) 1(0.5-3) 0.775 
Presence of frontal lobe atrophy 1(7.7%) 0 0.376 
Presence of parietal lobe atrophy 1(8.3%) 0 0.359 
Ventricle-brain ratio 0.38(0.31-0.41) 0.37(0.35-0.40) 0.795 
Presence of medial temporal lobe 
atrophy 






   
Figure 3- 1. 
Frontal lobe atrophy rating on CT (A1, A2) and MRI (B1, B2)  
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Figure 3- 2. 
PIB-PET and CT imaging of two subjects with early poststroke dementia  
Patient A: 87 male with new onset dementia after right occipital lobe infarct 
(A1), MMSE 19, CDR 2, medial temporal lobe atrophy rating of 2 (A2), no 
AD-like PIB retention (A3)  
 
Patient B: 79 male with transient left sided weakness for 30 minutes 
associated with acute cognitive decline; carotid duplex ultrasound showed 
50% stenosis of right internal carotid artery, cognitive impairment persisted 
till 3 months poststroke with MMSE 22 and CDR 1, CT showed no apparent 
infarct (B1), medial temporal lobe atrophy rating of 2 (B2),  AD-like PIB 




A1 A2 A3 
B1 B2 B3 
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Chapter 4 Stroke Registry Investigating Cognitive decline 




Background and Purpose: Having a stroke increases the risk of delayed 
dementia. However, mechanisms accounting for the cognitive decline are 
uncertain. We investigated the predictors for delayed poststroke cognitive 
decline.  
Methods: We recruited 549 subjects who were participants of the 
STRIVE-COG (STroke Registry InVEstigating COGnitive decline) study. We 
performed neuropsychological assessment at baseline (i.e. 3-6 months 
poststroke) and at 15-18 months poststroke. We defined cognitive decline as a 
drop of  3 points in the mini-mental state examination and/or increment in  
1 grading of the clinical dementia rating scale. We investigated the association 
between cognitive decline with baseline clinical, neuropsychological, and 
neuroimaging features (white matter changes severity, old lacunar infarct, 
global atrophy, frontal lobe atrophy, parietal lobe atrophy, medial temporal 
lobe atrophy). Among a subset of subjects (n=18) with poststroke dementia 
(PSD) at baseline, we investigated the influence of Alzheimer’s disease 




Results: Among 452(82.3%) subjects who had completed the study, cognitive 
decline occurred in 73 (16.2%) subjects. Age, education, and multiple lacunar 
infarcts independently predicted cognitive decline. Recurrent stroke occurred 
only in 5.1% and was not associated with cognitive decline. Progressive 
cognitive decline occurred in 41.7% and 33.3% of PIB negative (n=12) and 
PIB positive (n=6) PSD patients, respectively (p=0.731).  
Conclusion: Age, education, and multiple lacunar infarcts predicted cognitive 
decline at 15-18 months poststroke. Concurrent AD-like lesion is not 




Stroke survivors are at high risk of developing delayed cognitive decline.
21, 22
  
However, mechanisms explaining such decline remain uncertain in most cases. 
Although recurrent stroke probably accounts for some cases of delayed 
cognitive decline,
25, 69, 181
  majority of cases with delayed cognitive decline 
are unrelated to recurrent stroke.
21, 182
 In the PROGRESS (Perindopril 
Protection Against Recurrent Stroke Study), recurrent stroke only accounted 
for a quarter of cases with delayed dementia and majority was unrelated to 
recurrent stroke.
182
 Some hypothesized that concurrent Alzheimer’s pathology 
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may contribute to the cognitive decline. Yet, such claims lack support from 
pahtology or functional imaging (e.g. positron emission tomography [PET]) 
study.
25, 44 
To date, studies evaluating the predictors for delayed poststroke cognitive 
decline are few and the sample size for most studies was small. Moreover, the 
investigation on putative variables for individual study was not 
comprehensive enough. Most studies examined only clinical and cognitive 
profile without evaluation on imaging features.
25, 181, 183
  Furthermore, no 
studies had used PET imaging to evaluate the influence of concurrent 
Alzheimer’s pathology upon poststroke delayed cognitive decline.   
Understanding the mechanisms of delayed poststroke cognitive decline is 
crucial in devising preventive strategies. In this STRIVE-COG (STroke 
Registry IVEstigating COGnitive decline) study, we reported findings on the 
predictors for cognitive decline at 15-18 months poststroke. We evaluated 
clinical, cognitive, and structural neuroimaging data among a large cohort of 
stroke survivors. We also performed Pittsburgh compound B (PIB) PET and 
18F-fluoro-2-deoxy-glucose (FDG) PET among a subset of subjects with 
early poststroke dementia (PSD) and investigated the potential influence of 







Potential subjects of STRIVE-COG were those admitted to the acute stroke 
unit (ASU) of Prince of Wales hospital because of stroke (ischemic or 
hemorrhagic) or transient ischemic attack (TIA). Inclusion criteria for 
STRIVE-COG were Chinese ethnicity, fluent in Cantonese, ability to 
complete cognitive test, and provision of written informed consent. We 
excluded those with severe language, cognitive, motor, auditory or visual 
impairment that rendered patients unable to perform cognitive test, terminal 
illness with limited life expectancy, clinically significant depression or 
psychiatric co-morbidity, and refusal of participation. Ethics approval was 
obtained from the institution. The STRIVE-COG aimed to recruit patients 
who were admitted to the ASU from January 2009 through to December 2010 
(i.e. 2 years) and to follow-up these subjects for a period of 5 years. This study 
reported the findings based on subjects who were recruited over the first year 
(January to December 2009) and were followed-up for another year (i.e. 15-18 
months poststroke) after the baseline assessment (i.e. 3-6 months poststroke).   
   
Medical history 
In this registry, we collected baseline (i.e. 3-6 months poststroke) data on 
basic demography (age, gender, years of education, handedness), vascular risk 
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factors, history of previous stroke or TIA, previous medications, and 
secondary prevention therapies during hospitalization and after discharge. The 
presumed causes of stroke were defined at discharge, including hemorrhagic 
stroke, ischemic stroke, and TIA. Ischemic stroke/TIA was classified 
according to the TOAST (Trial of Org 10172 in Acute Stroke Treatment) 
criterion, which categorizes ischemic stroke into five subtypes based on the 
cause: large-artery atherosclerosis (LAA), small-artery occlusion (SAO), 
cardioembolism (CE), stroke of other determined cause, and stroke of 
undetermined cause.
158
 The neurologist in-charge of ASU patients classified 
stroke subtypes based on all available data before the patients were discharged 
from the unit. We performed the National Institute of Health Stroke Scale 
(NIHSS) for all patients shortly after admission.
 
Patients were diagnosed as having a history of hypertension, if they had 
evidence of systolic blood pressure >140 mm Hg and/or diastolic blood 
pressure > 90 mm Hg or a history of hypertension or use of antihypertensive 
medication. Diabetes mellitus was defined as fasting serum glucose  
7.0mmol/L, postprandial serum glucose  11.1mmol/L, or use of oral blood 
sugar-lowering drugs or insulin. Hyperlipidemia was defined as total 
cholesterol level of at least 5.2mmol/L, a low-density lipoprotein (LDL) 
cholesterol level of at least 2.6mmol/L, a triglyceride level of at least 
1.70mmol/L, and/or use of lipid lowering drugs. Ischemic heart disease was 
 68 
 
defined as the presence of myocardial infarction, angina pectoris, or other 
ischemic heart disease. Atrial fibrillation was diagnosed on the basis of at least 
one ECG before or during hospitalization. Smoking habit was categorized as 
ever smoking and non-smoking. Alcohol intake was recorded as ever drinking 
or non-drinking. 
At the second follow-up (i.e. 15-18 months poststroke), we recorded any 
new cerebral (i.e. recurrent stroke), cardiac events (i.e. acute coronary 
syndrome, congestive heart failure, and AF), and major surgery that occurred 
during the study period by reviewing the hospital computerized system, which 
captures every hospital attendance of the patients.  
 
Neuropsychological assessment 
All stroke/TIA patients were invited to return for a neuropsychological 
assessment at baseline (i.e. 3-6 months poststroke). We performed the clinical 
dementia rating (CDR) scale to grade the overall functional severity of 
cognitive impairment.
159
 The Chinese MMSE
160
 and the Hong Kong Montreal 
Cognitive Assessment (HK-MoCA)
161
 were used to index general cognition. 
We administered the Chinese version of the informant questionnaire on 
cognitive decline in the elderly (IQCODE) upon the subject’s reliable 
informant or caregiver to assess prestroke cognitive condition.
162
 The final 
score is the average of all scored items. We defined prestroke dementia when 
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the average score was ≥ 4 or the subjects had known history of dementia. We 




All subjects who participated in the baseline assessment were invited to 
return for the second assessment 1 year later (i.e. 15-18 months poststroke). At 
the second assessment, we repeated the following assessment: CDR, MMSE, 
HK-MoCA, and GDS. Trained psychologists performed all the above tests. 
Subjects with CDR ≥1 at either baseline or follow-up were further invited for 
another assessment by neurologists specialized in dementia (VM, LA) to 
confirm a diagnosis of dementia according to the Diagnostic and Statistical 






In this study, delayed cognitive decline was defined as a drop of ≥ 3 
points in the MMSE
182, 184
 and/or increment in the global CDR grading (e.g. 
grade 0 to 0.5 or above, or grade 0.5 to 1 or above)
185




Structural and vascular imaging  
A non-contrast brain computed tomography (CT) was performed with a 
multidetector row clinical CT scanner (10-mm slice thickness at 10-mm 
intervals supratentorially and 5-mm slice thickness and 5-mm intervals 
through the posterior fossa) for all subjects upon arrival to accident and 
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emergency department before admission to ASU. The CT imaging would be 
reconstructed into axial and coronal imaging for subsequent ratings. We 
performed brain magnetic resonance imaging (MRI) upon selected patients 
within 1 week of hospital admission, e.g. those with non-hemorrhagic and 
non-cardioembolic ischemic stroke, unclassified stroke etiology, without 
contraindication for MRI (e.g. unstable medical condition, metallic implants, 
claustrophobia). All MRI examinations were performed either on a 1.5 T 
scanner (Sonata, Siemens Medical, Erlangen, Germany) or a 3.0 T sacnner 
(Achieva 3.0 T TX Series, Philips Medical System, Best, the Netherlands) 
using standard protocols. The sequences include the following: diffusion 
weighted imaging (DWI), axial gradient echo (GE), axial spin echo (SE) 
T1-weighted fast field echo (FFE), turbo spin echo (TSE) proton density (PD) 
and T2 –weighted, axial FLAIR (Fluid attenuated inversion recovery), and 
time-of-flight (TOF) MR angiography (MRA) for 1.5-T MRI; and DWI, blood 
sensitive venous bold sequence, axial SE T1-weighted FFE, TSE 
T2 –weighted, axial FLAIR, TOF MRA for T-3 MRI.  
Trained technicians also performed transcranial Doppler (TCD) and 
carotid duplex ultrasound according to standard protocol
165
 for evaluation of 
intracranial and extracranial arteries, respectively, for patients with 
non-hemorrhagic and non-cardioembolic ischemic stroke / TIA. For TCD, the 
criteria for stenotic arteries were defined by the peak systolic flow velocity as 
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follows: ≥140 cm/s for the middle cerebral artery, ≥ 120 cm/s for the anterior 
cerebral artery, ≥ 100 cm/s for the posterior cerebral artery and vertebrobasilar 
artery, and ≥ 120 cm/s for the siphon internal carotid artery.165 Presence of 
any intracranial large artery stenosis on MRA and extracranial artery stenosis 
on carotid duplex was defined by a stenosis of ≥ 50%. In cases with 
conflicting TCD and MRA results, presence of intracranial artery stenosis was 




A trained neurologist (Yang Jie) who was blinded to the clinical and cognitive 
data recorded the following measures on stroke-related lesions: presence of 
hemorrhage, acute infarct measures (size and location), and laterality of 
ischemic or hemorrhagic lesions. The infarct size was categorized as lacunar if 
the infarction was between 3 and 20 mm in diameter; or non-lacunar if the 
infarct size was > 20mm. Location of acute infarct was classified as cortical, 
subcortical white matter, deep (basal ganglia, internal capsule, or thalamus), 
or infratentorial (cerebellum, brainstem). Acute infarct was defined by the 
presence of hyperintense MRI DWI lesions with corresponding hypointensity 
in the apparent diffusion coefficient map or hypodense lesions on CT that 
were relevant to the acute neurological signs and symptoms.
166
 With reference 






Chronic brain changes (white matter changes [WMC], old infarct, global and 
regional brain atrophy) 
The same neurologist (Yang Jie) who recorded stroke-related lesions also 
recorded following measures on chronic brain changes:  
1. WMC - Severity of WMC was rated on images obtained with FLAIR or CT 
scan using the Age-Related White Matter Changes Scale (ARWMC).
167
 We 
recorded the total and global ARWMC scores. The global score (range 0-3) is 
the score of the most severe region, with score 0, 1, 2, and 3 representing no, 




2. Old infarct - We recorded the presence of old lacunar and old non-lacunar 
infarcts, which were not clinically relevant to the index stroke. Old lacunar 
infarct was defined as hypodense foci 3 mm to 20mm larger on CT scan or as 
hypointense lesion on FLAIR (with or without a hyerintense rim) and on 
T1-weighted images. We recorded the total number and the location of old 
lacunar infarct. Subjects with >2 old lacunar infarcts were considered as 
having multiple lacunar infarcts. Location of old lacunar infarct was classified 
as frontal lobe, parieto-occipital lobe, basal ganglia, thalamus and 
infratentorial region. 
169
We recorded only the number of old non-lacunar 
infarct. 
 
3. Brain atrophy - We used the ventricle-to-brain ratio (VBR) to index global 
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or subcortical atrophy. The VBR was calculated as the mean of the 
biventricular width at the level of the frontal and occipital horns and at the 
level of the body of the caudate nuclei divided by the corresponding brain 
width at those levels on either MRI or CT.
170
 We graded frontal lobe atrophy 
(FLA) and parietal lobe atrophy (PLA) using a 3-point (0-2) scale.
171
 Rating 
of FLA was carried out on axial T1-weighted MRI or CT images. Rating of 
PLA was carried out on coronal T1-weighted MRI or CT oblique coronal 
reconstructed images. Subject with a rating of  1was classified as having 
FLA or PLA. Medial temporal lobe atrophy (MTLA) was rated on coronal 
images on T1-weighted MRI or CT oblique coronal reconstructed images 
using the Scheltens’ scale.172 Subject with a rating of  2 was classified as 
having MTLA. For subjects who had both CT and MRI, above ratings were 
performed only upon MRI. 
 
To investigate whether the visual rating methods for chronic brain 
changes WMC, VBR, FLA, PLA, and MTLA are applicable to both CT and 
MRI, we performed intermodality agreement between CT and MRI based on 
random selection of 30 subjects’ scans. The agreement for WMC (intraclass 
correlation coefficient ICC 0.82), VBR (ICC 0.85), FLA (percentage of 
agreement 0.94), left MTLA (ICC 0.86), was excellent. There was also good 
agreement for PLA (percentage of agreement, 0.78) and right MTLA (ICC 
0.58). The intrarater agreement between two measurements within 6 months 
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for a single rater (JY) among random selection of 30 scans was also excellent 
for CT (WMC ICC, 0.93, VBR ICC 0.92, FLA percentage of agreement 
0.99, PLA percentage of agreement 0.99, left MTLA ICC 0.99, right 
MTLA ICC 0.98 ); and MRI (WMC ICC 0.96, VBR ICC, 0.95, FLA 
percentage of agreement 0.99, PLA percentage of agreement 0.99, left 
MTLA ICC, 0.92, right MTAICC, 0.94 ).  
 
FDG and PIB-PET scan 
Patients with early PSD diagnosed at baseline were potentially eligible for 
FDG and PIB PET. Exclusion criteria for PET imaging were as follow: 1. 
patients with known AD or other degenerative dementing disorders (e.g. 
frontotemporal dementia) before stroke; 2. patients without reliable informants; 
3. patients who suffered from severe stroke with significant cognitive and 
motor disability; and 4. those who refused to participate in this PET study. We 
obtained a separate ethics approval from the institution for this PET study and 
all subjects and their caregivers provided written informed consent. Brain CT 
transmission and PET imaging began after PIB injection for 5, 35 and 60 
minutes and then static imaging began at 30 minutes after FDG administration. 
All images were reviewed by a specialist in nuclear medicine (Eric Leung). 
Subjects with predominant increase in PIB binding observed visually at the 
frontal cortex, posterior cingulate, precuneus, caudate, parietal cortex, and/or 
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lateral temporal cortex were considered as having AD-like PIB binding.
128
  
On FDG PET, presence of bilateral temporoparietal and posterior cingulate 




We compared data between groups using χ2, unpaired 2-taied t test, or 
Mann-Whitney U test. Difference with a p value <0.05 was considered 
significant. Regression modeling was used to identify predictors that 
independently associated with delayed poststroke cognitive decline with 
variables showing P <0.05 in the univariate tests. For the investigation on the 
predictors, we analyzed the following variables: baseline basic demographics, 
stroke subtypes, vascular risk factors (smoking, alcohol consumption, 
hypertension, hyperliperdemia, diabetes mellitus, previous TIA, previous 
ischemic stroke, previous hemorrhagic stroke, atrial fibrillation, ischemic 
heart disease, congestive heart failure, medications upon discharge to ASU, 
MMSE, HK-MoCA, CDR grading, GDS, measures of stroke-related lesions 
(acute infarcts, hemorrhage), presence of intracranial and extracranial large 
artery stenosis, chronic brain changes (WMC, old infarcts, VBR, FLA, PLA, 
MTLA), and recurrent stroke. For atrophy measures, we used the presence or 
absence of FLA, PLA, and MTLA. For global brain atrophy, we compared the 
percentage between the 4 quartiles. For ARWMC, we used the total score as 
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continuous variable. Statistical tests were performed by SPSS for Windows 
(release 16.0, SPSS Inc). 
 
4.4 Results 
Five hundred and forty-nine stroke survivors completed baseline assessment 
at 3-6 months poststroke and were invited for second follow-up. At 15-18 
months poststroke, 452 (82.3%) subjects completed the second assessments 
(mean age, 69.1years; 45.8% female) (table 4-1). Reasons for dropping out 
were death (n=30, 5.4%), refusal (n=28, 5.1%), inability to attend assessment 
because of severe physical impairment (n=27, 4.9%), and missing of major 
cognitive data (n=22, 4.0%). Patients who dropped out were older (74 vs 70, 
p=0.01), had lower median MMSE (23 vs 26, p<0.001), higher ARWMC total 
score (4 vs 1, p=0.001) relative to the completers. MTLA was also more 
common among the non-completers relative to completers (41.7% vs 30.8%, 
p=0.039). There was no significant difference in terms of other basic 
demographic, clinical, and neuroimaging characteristics.     
Among the 452 subjects, 392 subjects were dementia-free at baseline 
assessment. Among the 452 subjects, 73 (16.2%) subjects had cognitive 
decline at the second assessment. Among the 392 subjects who were 
dementia-free at baseline, 59 (15.1%) subjects had cognitive decline and 7 
(1.8%) subjects developed incident dementia. If TIA patients (n=44) were 
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excluded, rate of incident dementia was 2.9% (i.e. 7 / 348).  
 
Predictors for delayed poststroke cognitive decline 
Table 4-2 shows the variables that were significant in the univariate analysis 
in predicting delayed poststroke cognitive decline among all subjects. 
Forward stepwise logistic regression analysis found that age (odds ratio [OR] 
=1.099, 95% confidence interval [CI] 1.031-1.173, p=0.004), education 
(OR=0.902, 95% CI, 0.838-0.970, p=0.006), and multiple lacunar infarcts 
(OR=2.825, 95%CI, 1.447-5.494, p=0.002) predicted poststroke delayed 
among all subjects (Table 4-3). Among dementia-free stroke subjects, forward 
stepwise logistic regression analysis found that education (OR=0.891, 95% CI, 
0.800-0.993, p=0.037) and multiple lacunar infarcts (OR=3.020, 95%CI, 
1.149-7.940, p=0.025) predicted delayed cognitive decline. Recurrent stroke 
occurred only in 23 (5.1%) subjects during the study period and it was not 
associated with cognitive decline.  
 
Delayed cognitive decline in patients with PET imaging  
At baseline, 19 survivors with PSD had PIB and FDG PET imaging. Among 
these subjects, 6 had PIB retention typical of AD and all these 6 subjects also 
showed temporoparietal and posterior cingulate hypometabolism typical of 
AD (Figure 4-1). At end of follow-up, 1 PIB negative case dropped out 
 78 
 
because of death secondary to congestive heart failure. Among the remaining 
18 cases who had second follow-up, cognitive decline occurred in 41.7% (n=5) 
and 33.3% (n=2) of PIB negative (n=12) and PIB positive (n=6) PSD patients, 
respectively (p=0.731) (Table 4-4).   
 
4.5 Discussion 
We found that apart from age and education, multiple lacunar infarcts 
predicted delayed cognitive decline at 15-18 months poststroke. We also 
observed that concurrent presence of AD-like lesion was not necessary 
associated with a more rapid cognitive decline compared to those without 
AD-like lesion. Similarly, a progressive cognitive decline poststroke is not 
necessary related to concurrent AD. Our findings suggest that stroke patients 
harboring multiple old lacunar infarcts are at high risk of delayed progressive 
cognitive decline.  
Our findings that multiple lacunar infarcts predicted cognitive decline 
concur with another study, showing that multiple lacunar infarcts predicted 
incident dementia in stroke patients.
44
 Our findings are also consistent with 
community studies among stroke- and dementia-free elderly subjects showing 
that silent lacunar infarcts  increased risk of dementia.
186, 187
 Although 
etiology of lacunar infarct can be multiple (e.g. larger artery atherosclerosis, 
cardioembolism), by far the commonest cause is cerebral SVD. Multiple 
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lacunar infarcts probably reflect greater disease severity. Some suggested that 
“multiple lacunar infarcts” represent a more malignant form of SVD, having a 
poorer prognosis and different pathophysiology than “isolated lacunar   
infarct”.188 The Rotterdam Scan Study showed that cognitive decline in 
subjects harboring silent lacunar infarcts were mostly related to development 
of additional new infarcts.
187
  Mechanisms explaining how lacunar infarcts 
impair cognition include interruption of frontal-subcortical circuits that are 
responsible for executive function and/or its association with brain atrophy.
44, 
189
 However, we are unable to determine whether additional infarcts are 
associated with cognitive decline because we did not perform serial 
neuroimaging. 
 
Some proposed that delayed cognitive decline in stroke or in subjects 
with lacunar infarcts is mainly related to interaction with concurrent 
Alzheimer’s pathology.44, 187, 190 However, we observed that among the 6 
subjects who had AD-like lesions as detected by PET imaging, only 2 had 
delayed cognitive decline. In fact, community study showed that AD-like PIB 
retention could be found in about 30% of dementia-free elderly subjects.
178
 A 
longer study is probably needed to determine whether AD-like PIB retention 
dose interact with cerebrovascular disease or lacunar infarcts in causing a 
more rapid cognitive decline. Noteworthy is that our study showed that 
delayed progressive cognitive decline occurred in about 40% of PIB negative 
 80 
 
subjects, hence progressive cognitive decline poststroke is not necessary 
associated with concurrent AD pathology or other neurodegenerative diseases.
 
Our finding that severity of WMC did not predict delayed cognitive 
decline in stroke patients concurs with some,
44, 190
 but not all studies.
43, 184, 191
 
We also failed to find an association between various measures of brain 
atrophy (e.g. global atrophy and MTLA) with delayed cognitive decline. This 
is in contrast to majority of studies showing a positive relationship between 
global brain atrophy or MTLA with delayed cognitive decline in stroke 
patients.
43, 44, 190
 Since our follow-up duration (15-18 months poststroke) is 
slightly shorter than the above positive studies, (2-4 years poststroke), 
whether a longer follow-up may yield a positive relationship brain atrophy 
with delayed cognitive decline requires further investigation.
 
Recurrent stroke was not found to predict delayed cognitive decline in 
our study, as had been noted in earlier studies.
25, 69, 181, 191
 This is probably 
related to the small number of subjects (5.1%, n=23) who had recurrent stroke 
during the 1 year study period. This low rate of ~ 5% recurrent stroke per year 
is indeed comparable to recent trends showing that rate of recurrent stroke had 
dropped from around 9% in 1960s to only 5% in 2000s.
192 
The strengths of our study are its large sample size, its prospective design, 
a high retention rate, and the evaluation of a large number of clinical, 
neuropsychological, and neuroimaging data. We were also able to evaluate 
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in-vivo the presence or absence of concurrent AD lesions upon delayed 
cognitive decline. However, certain methodological issues should be 
addressed. Since we do not have serial imaging, we are unable to evaluate the 
influence of potential cerebral changes (e.g. incident lacunar infarcts, 
increasing WMC or brain atrophy) upon cognitive decline. Second, we used 
global measures (i.e. MMSE and CDR) to monitor cognitive changes. Hence, 
more subtle cognitive decline or decline mainly involving the executive 
domain may not be detected by these scales. Third, we used visual, rather than 
volumetric methods for assessment of chronic brain changes. Hence, the 
influence of smaller volumetric changes of these chronic brain changes upon 
delayed cognitive decline might not be detected. Last, number of subjects who 
had PET imaging was small (n=18) and only 6 subjects were detected to have 
AD-like lesions. Hence, our PET findings require a larger study for 
confirmation.  
In conclusion, the presence of multiple lacunar infarcts identifies stroke 
patients who are at increased risk for delayed cognitive decline. Further 
studies are needed to clarify the mechanisms explaining the cognitive decline. 
More important, clinical trials targeting this high-risk group and incorporate 






Table 4- 1. 
Clinical, neuropsychological, and neuroimaging characteristics of all 





(n = 452) 
Basic demographic features   
Age, median (IQR) 70(61-78) 
Education year, median (IQR) 5(1-9) 
Female 207 (45.8) 
Clinical features or vascular risk factors  
NIHSS on admission ,median (IQR) 4(2-6) 
Stroke types  
Large-artery atherosclerosis 132(29.2) 
Small-artery vessel occlusion 159(35.2) 
Cadioembolism 89(19.7) 
Intracranial hemorrhage 26(5.8) 
Others 46(10.2) 
Smoking 124 (27.4) 
Alcohol consumption   40 (8.8) 
Diabetes mellitus 175 (38.7) 
Hyperlipidemia 259 (57.3) 
Hypertension 312 (69.0) 
Atrial fibrillation 75 (16.6) 
Ischemic heart disease 44 (9.7) 
Congestive heart failure 13 (2.9) 
Previous transient ischemic attack 19 (4.2) 
Previous hemorrhagic stroke 12 (2.7) 
Previous ischemic stroke 62 (13.7) 
Recurrent stroke during follow-up 23 (5.1) 
Intracranial large artery stenosis 169 (54.5) 
Extracranial large artery stenosis  43 (15.8) 
Intra and extracranial large artery stenosis  187 (66.5) 
Neuropsychological features  
Clinical Dementia Rating scale  
0 196 (43.4) 
0.5 182 (40.3) 
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1-3 60 (13.3) 
Mini-mental state examination at baseline,median 
(IQR) 
26(20-28) 
Montreal Cognitive Assessment at baseline, median 
(IQR) 
21(16-25) 
Geriatric Depression Scale at baseline, median (IQR) 5(2-8) 
Stroke-related lesions  
Presence of acute infarct 259 (57.3) 
Size of acute infarct      
Non-lacunar    133 (29.5) 
Lacunar 126 (27.8) 
Acute infarct location  
Cortical 60 (13.3) 
Subcortical 96 (21.2) 
Deep 50 (11.1) 
Infratentorial 53 (11.7) 
Acute infarct lateralization  
Dominant  96 (21.2) 
Nondominant 110 (24.3) 
Infratentorial 53 (11.7) 
Neuroimaging features on chronic brain changes      
ARWMC total score, median (IQR) 1(0-6) 
Presence of old lacunar infarcts  205(45.6) 
Presence of multiple lacunar infarcts (i.e. >2) 84(18.7) 









Presence of frontal lobe atrophy 50 (11.1) 
Presence of parietal lobe atrophy 43 (9.7) 
Presence of medial temporal lobe atrophy 137 (30.8) 
Values are number (%) unless otherwise stated; IQR = interquartile range; SD = 






Table 4- 2. 
Comparison bewteen subjects with and without delayed cognitive decline 
among among all participants   
 






Age, median (IQR)) 69(60-77) 73.5(65-90) 0.004 
Education years, median IQR) 5(2-9) 3(0-6) 0.001 
NIHSS on admission, median( IQR) 3(1-6) 5(3-8) 0.012 
Stroke subtypes   0.026 
Large-artery atherosclerosis 101(26.9) 31(40.8)  
Small-artery occlusion  143(38.0) 16(21.1)  
Cardioembolism  71(18.9) 18(23.7)  
Intracranial hemorrhage 21(5.6) 5(6.6)  
Others 40(10.8) 6(7.9)  
Montreal Cognitive Assessment score at 
baseline , median IQR) 
22(16-25) 18(13-22) <0.001 
ARWMC total score 1(0-4) 2(0-8) 0.007 
Old lacunar infarct number, median(IQR) 0(0-2) 1(0-3) 0.008 
Presence of multiple lacunar infarcts 
(i.e. >2) 
59(15.7) 25(33.3) <0.001 
Ventricular-brain ratio quartiles   0.019 
1
st 113(30.9) 10(14.5)  
2
nd 105(28.7) 21(30.4)  
3
rd 73(19.9) 15(21.7)  
4
th 75(20.5) 23(33.3)  
Presence of medial temporal lobe atrophy 108(28.9) 29(40.8) 0.045 
Values are number (%) unless otherwise stated; SD = standard deviation; ARWMC= 












Table 4- 3. 
Multivariate regression model for predictors of delayed cognitive decline 











0.095 1.099  1.031 -1.173 0.004 
Education years 
-0.103 0.902 0.838 -0.970 0.006 
Multiple lacunar infarcts 


































Table 4- 4. 
Comparison between poststroke dementia patients with and without PIB 
retention 
Values are number (%) unless otherwise stated; IQR = interquartile range  













Age, median (IQR) 81.5(64.5-85) 78(73.7-80.7) 0.750 
Male 9(75) 3(50.5) 0.294 
Education, median years (IQR) 3.5(0-9) 3(1-10) 0.953 
Stroke subtypes   0.097 
Large-artery atherosclerosis 1(8.3) 3(50.0)  
Small-artery occlusion  5(41.7) 0  
 Cardioembolism  2(16.7) 1(16.7)  
 Intracranial hemorrhage 3(25) 2(33.3)  
Other types 1(8.3) 0  
Mini-mental state examination change, 
median (IQR) 
0(-1-1.5) -1(-5.5-6) 0.776 
Montreal Cognitive Assessment change, 
median (IQR) 
0(-2-1.5) 2(-5-8.5) 0.562 
Cognitive decline (i.e. drop of MMSE ≥ 3)   3(41.7) 2(33.3) 0.731 
ARWMC scale total score, median (IQR) 8(3.2-12) 6(1.5-9) 0.494 
Old lacunar infarct number, median (IQR) 1.5(0.3-5) 1(0.5-3) 0.646 
Presence of lacunar infarct 9(75) 4(80.0) 0.823 
Presence of multiple lacunar infarcts  
(i.e. > 2) 
5(41.7) 1(20) 0.380 
Ventricle-brain ratio 0.39(0.33-0.41) 0.37(0.35-0.40) 0.820 
Presence of frontal lobe atrophy 1(10.0) 0 0.359 







Figure 4- 1. 
Neuroimaging of 2 subjects who had cognitive decline during follow-up 
and had PIB-PET imaging 
Patient A: 87 male with poststroke progressive cognitive decline, baseline and 
follow-up MMSE = 19 and 12, CT showed multiple lacunar infarcts and 
periventricular white matter changes (A1), no recurrent stroke during 
follow-up, no AD-like PIB retention (A2)  
 
Patient B: 70 male admitted with transient ischemic attack associated with 
atrial fibrillation, CT head showed moderate white matter changes (B1); 
progressive cognitive decline with baseline and follow-up MMSE = 21 and 12; 








































Chapter 5 Strengths and Limitations   
Most of the strengths and limitations of the studies had been mentioned 
already as above. The strengths of our study are its large sample size, its 
prospective design, and the evaluation of a large number of clinical, 
neuropsychological, and neuroimaging data. We recruited consecutive patients 
admitted to our ASU into our studies, which reduces selection bias and hence 
increases the validity of our findings. We were also able to evaluate in-vivo 
the presence or absence of concurrent AD lesions upon subjects with early 
PSD and delayed cognitive decline.  
Certain limitations should however be addressed. First, only half of the 
cases had MRI. Smaller acute or old lacunar infarcts and mild severity of 
WMC could not be visualized well by CT. We might thus have underestimated 
the cognitive impact of these lesions. Yet, this registry probably reflects the 
reality of many stroke units where MRI is not easily accessible, especially 
those in developing countries like China, where the burden of PSD is the 
greatest. Second, we used visual, rather than volumetric methods for 
assessment of chronic brain changes. Hence, despite we obtained good to 
excellent intermodality and intrarater agreement for our visual methods, the 
influence of smaller volumetric changes of these chronic brain changes might 
not be detected. Third, we did not evaluate the influence of microbleeds upon 
cognition in our cohort as only half of the subjects had MRI. Fourth, despite 
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this is the first prospective study utilizing PIB PET in the evaluation of PSD, 
the proportion of early PSD patients who eventually had PIB-PET was small 
(22.6%) and PIB retention was found only in 6 subjects. Fifth, PET imaging 
was not performed among stroke subjects without dementia.  
As for the second study, since we do not have serial imaging, we were 
unable to evaluate the influence of potential cerebral changes (e.g. incident 
lacunar infarcts, increasing WMC or brain atrophy) upon cognitive decline. 
Second, we used global measures (i.e. MMSE and CDR) to monitor cognitive 
changes. Hence, more subtle cognitive decline or decline mainly involving the 
executive domain may not be detected by these scales. Third, we used visual, 
rather than volumetric methods for assessment of chronic brain changes. 
Hence, the influence of smaller volumetric changes of these chronic brain 
changes upon delayed cognitive decline might not be detected. Last, number 
of subjects who had PET imaging was small (n=18) and only 6 subjects were 












Chapter 6 Summary and Future Directions 
We conducted 2 prospective studies investigating the risk factors for early 
PSD and predictors for delayed cognitive decline among a large cohort of 
Chinese stroke patients. For early PSD, we found that apart from age, female 
gender, and presence of acute infarct detected in neuroimaging, chronic brain 
changes (WMC, global brain atrophy, FLA) were associated with early PSD; 
while age, education, and multiple old lacunar infarcts predicted cognitive 
decline at 15-18 months poststroke. Interestingly, we found that although 
concurrent AD-like lesion was not uncommon in PSD subjects, its presence 
was not necessary associated with a rapid cognitive decline. 
Our findings highlight the importance of these chronic brain changes in 
the evolution of early or delayed poststroke cognitive decline. It is possible 
that PSD can be reduced or poststroke cognitive decline can be slowed down 
if effective treatments targeting these chronic changes are available. Future 
studies should look into the risk factors associated with the development and 
progression of these brain changes and should explore preventive treatments 
using these brain changes as surrogate outcomes. Preferably, such clinical 
trials should be conducted at the pre-dementia stage as primary prevention 
provides the greatest opportunity to reduce the dementia burden. For example, 
dementia-free stroke survivors who harbor multiple old lacunar infarcts 
should be recruited for clinical trials; or clinical trials can also recruit stroke- 
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and dementia-free community dwelling subjects who have subclinical 
confluent WMC or significant brain atrophy. Moreover, larger and longer 
clinical in-vivo studies using amyloid PET are needed to unravel the complex 
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